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1 Introduction 
 
1.1 Interleukin 6 
The pleiotropic cytokine Interleukin 6 (IL-6) was originally identified as an antigen-
independent B-cell differentiation factor that activates B-cells to produce 
immunoglobulins (1, 2). Meanwhile it is known that IL-6 is involved in a wide range of 
biological activities in immune regulation and it is secreted by various lymphoid cell 
types, such as T-cells, B-cells, macrophages and monocytes (3). Apart from 
lymphoid cells, IL-6 is produced also by various types of nonlymphoid cells, such as 
fibroblasts, keratinocytes, endothelial cells and several tumor cells (3). 
Altered levels of IL-6 have been found in a variety of diseases including multiple 
myeloma, Crohn's disease, mesangial glomerulonephritis, osteoporosis, cardiac 
ischemia, cachexia and rheumatoid arthritis (4).  
IL-6 has been described to have pro- as well as anti-inflammatory properties (5, 6). In 
fact, it promotes inflammation through the expansion and activation of T-cells, 
differentiation of B-cells and the induction of acute-phase response by hepatocytes 
(6). Furthermore IL-6 is produced in large amounts by endothelial cells in response to 
proinflammatory signals including TNF-α (7) and hypoxia (8).  
Due to its high ability to activate an inflammatory response, IL-6 expression is strictly 
regulated and the protein is hardly expressed under steady state conditions. It is 
commonly produced at local tissue sites and is released in case of tissue damage, 
which could be infection, injury and endotoxaemia. IL-6 can also become chronically 
elevated, resulting in a number of serious diseases.  
 
In the liver,  IL-6 acts as a major regulator of the hepatic acute phase response by 
stimulating hepatocytes to produce C-reactive protein, fibrinogen and serum amyloid 
A (9). Furthermore IL-6 induces differentiation of cytotoxic T-cells by enhancing the 
production of IL-2 and IL-2 receptor (10) and differentiation of macrophages (11). 
Additionally, circulating IL-6 together with tumor necrosis factor α (TNF-α) and 
interleukin-1 (IL-1) cause fever and induce leukocytosis which is valuable for 
pathogen elimination (12). 
Homozygous IL-6 knockout (IL-6-/-) mice develop normally but show a compromised 
acute phase response after tissue damage or infection, which becomes evident in the 
lacking ability to control bacterial infections like infection with Listeria monocytogenes 
and an impaired T-cell dependent antibody response (13).  Additionally, IL-6-/- mice 
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are completely protected from chronic inflammatory diseases such as collagen-
induced arthritis (14) and are resistant to experimental autoimmune 
encephalomyelitis (EAE), an animal model for multiple sclerosis (15).  
In conclusion, the phenotype of the IL-6-/- mice emphasizes that IL-6 is an eminent 
cytokine involved in regulation of host response after infection and plays an important 
role in controlling immune regulation.  
 
1.2 Classical IL-6 signaling 
The IL-6-type family of cytokines acts via receptor complexes that contain at least 
one subunit of the signal transducing glycoprotein 130 (gp130). The family comprises 
Interleukin-6 (IL-6), Interleukin-11 (IL-11), viral IL-6, IL-27, IL-31, neuropoietin (NP), 
leukaemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor 
(CNTF), cardiotropin-1 (CT-1) and cardiotrophin-like cytokine (CLC) (16, 17). 
Each member of the IL-6 type family of cytokines is characterized by a certain pattern 
of receptor recruitment.  
IL-6, IL-11 and CNTF first bind to their corresponding nontransducing α -receptor, 
which subsequently leads to the recruitment and dimerization of the signaling 
subunits gp130 and LIFR (18). IL-6 and IL-11 signal via a homodimer of two gp130 
subunits (Fig. 1). CNTF recruits one gp130 subunit and one LIF receptor (LIFR) 
subunit. LIF, CT-1, IL-27, IL-31, viral-IL-6 and OSM can directly interact with their 
signaling receptor subunits without requiring an α-receptor subunit (19). The cytokine 
CLC can only bind to the signal transducing subunits gp130 and LIFR in the 
presence of the additional soluble cytokine receptor soluble CNTFR (20).  
gp130 gp130
IL-6R
IL-6
Classic Signaling
 
Figure 1: Classical IL-6 Signaling. IL-6 first binds to its specific nontransducing α –receptor (IL-6 
Receptor), which subsequently leads to the recruitment and dimerization of two signaling subunits 
gp130. 
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Dimerization of the signal transducing subunits gp130 leads to activation by 
phosphorylation of the Janus kinases (JAK) (21) (Fig. 2).  
Activated JAK kinases phosphorylate tyrosine residues at the cytoplasmatic domain 
of gp130. This leads to the recruitment of SH2 domain proteins like SHP-2 and STAT 
proteins. There are six tyrosine residues in gp130 and phosphorylation of the four 
distal tyrosines leads to recruitment and activation of the signal transducer and 
activator of transcription (STAT) proteins (22). 
 
 
Figure 2: IL-6 activates the JAK/STAT pathway and the MAPK cascade. Representation of the two 
major pathways activated by IL-6-type cytokines. TF, transcription factor (16). 
 
 IL-6 binding leads to an activation of STAT3 and STAT1 (23, 24). Directly after 
tyrosine phosphorylation, STATs form homo- and heterodimers and translocate to the 
nucleus. Subsequently, transcription of target genes is activated, including those 
involved in inflammation, acute phase response (e.g. C-reactive protein (25) and 
Lipopolysaccharide (26)) and proliferation (like c-Fos (27) and Jun B (28)).  
 
PIAS3 (Protein inhibitor of activated STAT3) blocks the DNA binding activity of 
STAT3 and inhibits STAT3-mediated gene activation. Although STAT1 is also 
phosphorylated in response to IL-6, PIAS3 do not interact with STAT1 or affect its 
DNA-binding or transcriptional activity. Therefore is PIAS3 a specfic inhibitor of 
STAT3 signaling pathways (29).  
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A second way to down-regulate the STAT pathway is the negative feedback inhibitor 
SOCS (suppressor of cytokine signalling). The transcription of the SOCS proteins is 
induced by STAT3. SOCS proteins bind to the SHP2 (SH2-domain-containing 
tyrosine phosphatase)- binding site Tyr759 of gp130 and reduces the MAPK (Ras 
mitogen-activated protein kinase) cascade (30, 31). SOCS1 and SOCS3 are 
functionally most related and potently inhibit IL-6-type signaling. Both have been 
shown to act on the JAKs, and thereby inhibit the phosphorylation of gp130, STATs 
and the JAKs themselves (31, 32). 
 
Dimerization of IL-6-type cytokine receptors does not only lead to activation of the 
JAK/STAT-signalling pathway, but also to the induction of the MAPK cascade. The 
binding of SHP2 to Tyr759 of gp130 was identified to be crucial for the activation of 
MAPK cascade (33). SHP2 is rapidly recruited to tyrosine-phosphorylated gp130 and 
becomes also phosphorylated in a JAK1-dependent manner. Subsequently, tyrosine-
phosphorylated SHP2 interacts with Grb2 and two C-terminal tyrosine residues within 
SHP2 and this interacts with the Grb2–SOS complex. Finally, recruitment of SOS to 
the receptor complex at the membrane allows Ras activation, which in turn leads to 
the activation of the Ras–Raf–MAPK cascade (16). 
 
1.3 IL-6 Transsignaling 
As described before, IL-6 first binds to its specific nontransducing α –receptor, the IL-
6 Receptor (IL-6R), which subsequently leads to the recruitment and 
homodimerization of two signaling subunits gp130 and to gene activation via 
signaltransduction of the Jak/STAT pathway. 
While gp130 is expressed on all cell types, expression of the IL-6 Receptor (IL-6R) is 
restricted to hepatocytes and some leukocyte sub-populations including monocytes, 
neutrophils and some T-cells (CD4+, CD8+, CD4+CD25- and CD25high regulatory T-
cells (34)) and B-cells subtypes (6, 19). 
Cells lacking the IL-6R are not able to respond to IL-6 through the classical IL-6 
pathway. However, a naturally occuring soluble form of the IL-6R, which is generated 
either by limited proteolysis of the membrane-bound IL-6R (35) or by translation from 
an alternatively spliced mRNA (36), can bind to IL-6. Thereby, the soluble IL-6R 
binds IL-6 with the same affinity as membrane-bound IL-6R and the complex of IL-6 
and sIL-6R can stimulate cells lacking membrane-bound IL-6R, but expressing gp130 
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(Fig. 3). This alternative IL-6 signaling pathway has been named Transsignaling (37-
39). 
gp130 gp130
IL-6/
sIL-6R complex
IL-6 Transsignaling
Signal
gp130 gp130
IL-6/
sIL-6R complex
IL-6R
IL-6
ADAM shedding
Soluble IL-6R
ADAM shedding
Activate cells lacking
membrane-bound IL6R
 
Figure 3: IL-6 Transsignaling. Soluble IL-6R, which is generated either by limited proteolysis of the 
membrane-bound IL-6R or by translation from an alternatively spliced mRNA binds IL-6 with the same 
affinity as membrane-bound IL-6R. The complex of IL-6 and sIL-6R can stimulate cells lacking 
membrane-bound IL-6R. 
 
Shedding of the IL-6 receptor can be initiated by different stimuli such as phorbol 
ester (35), C-reactive- protein (40), pore-forming toxins (41), cholesterol depletion 
(42) and apoptosis (43). While constitutive shedding of the IL-6R is mediated by 
ADAM10 (A disintegrin and metalloproteinase 10), induced cleavage is arranged by 
the metalloprotease TACE (ADAM17) (42).  
 
In healthy humans, the naturally occuring soluble form of the IL-6R is found in the 
blood at concentrations of about 50-80 ng/ml (44). sIL-6R levels increase in some 
inflammatory diseases such as peritonitis (45) and rheumatoid arthritis (46) by a 
factor of 2. 
IL-6 Transsignaling has been shown to be relevant in a variety of physiological and 
pathophysiological processes, including T-cell-and lymphocyte-trafficking and-
infiltration (12, 47, 48), osteoclast formation (49), smooth muscle cell activation (50), 
Crohn`s disease and colon cancer (51-53). 
In conclusion, the IL-6/sIL-6R complex has, due to the ubiquitous expression of 
gp130, the potential to stimulate all cells of the body. 
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1.4 Agonists and Antagonists of IL-6 Transsignaling 
Soluble cytokine receptors can either act as antagonists competing with the 
membrane bound receptors for their cognate ligands or they can act as agonists.  
Most of the soluble cytokine receptors, e.g. IL-1R (54), TNF-R (55) and IL-4R (56) 
function as antagonists by competing against their membrane-bound 
correspondents.  
The soluble IL-6R is an agonistic soluble cytokine receptor that binds its ligand IL-6 
with comparable affinity as the membrane bound IL-6R. Cells that only express 
gp130 but no IL-6R cannot be stimulated by IL-6, unless a soluble form of the IL-6R 
is present (57).  
To  mimic IL-6 Transsignaling a designer cytokine, Hyper-IL-6, has been constructed. 
Hyper-IL-6 is a fusion protein consisting of IL-6 and the soluble IL-6R, which are 
connected via a flexible peptide linker. Thereby the association of the ligand/receptor 
complex is achieved (58).  
Hyper-IL-6 is 100 to 1000 times more potent to induce biological reactions than the 
two separate proteins IL-6 and sIL-6R. IL-6 alone binds with an affinity of 10-9M to the 
IL-6R, whereas IL-6/ IL-6R complex binds the gp130 protein with an affinity of 10-11M 
(58, 59). 
Moreover, the accelerating effect of Hyper-IL-6 has been described in liver damage 
and regeneration (60, 61).  
In addition to the soluble IL-6R exists a soluble form of gp130 protein (sgp130). 
Levels of sgp130 (100-400 ng/ml) have been detected in human blood. This sgp130 
can bind to the IL-6/sIL-6R complex, but not to IL-6 alone and thereby inhibits 
signaling via membrane bound gp130 (62). It has been concluded that sgp130 
functions as the natural inhibitor of IL-6 Transsignaling but not of classical IL-6 
signaling (Fig. 4) (63). 
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Figure 4: Soluble gp130 mediated inhibition of IL-6 Transsignaling. sgp130 is binding the IL-6/sIL-
6R complex and thereby inhibiting signaling via membrane bound gp130. As a consequence sgp130 
function as the natural inhibitor of IL-6 Transsignaling but not of classical IL-6 signaling. 
 
A variant of sgp130, called sgp130Fc, was designed by fusing the complete 
extracellular region of murine gp130 with the Fc-part of a human IgG1-antibody. It 
has been shown that dimerized sgp130Fc is able to inhibit IL-6/sIL-6R-mediated 
Transsignaling with a 10-fold higher activity than monomeric sgp130 (63). This 
sgp130Fc designer molecule can be used as a molecular tool to distinguish between 
classic IL-6 and IL-6 Transsignaling. 
It has been shown that sgp130Fc can abrogate inflammation in a transgenic mouse 
model, in which IL-6 Transsignaling is blocked (64).  
 
1.5 Structure of the liver  
With 2% of total body weight is the liver one of the largest organs of humans with 
crucial function in synthesis, storage, metabolization and detoxification. The liver is 
the primary organ for detoxification of toxins, drugs or other pollutants.  
It is divided into a larger right and a smaller left lobe (Fig. 5). On the caudal side of 
the liver are the major afferent vessels (hepatic artery, portal vein) and the common 
bile. On the cranial side the liver veins end into the vena cava inferior (63, 64). 
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Figure 5 : Human liver division into eight segments (I-VIII). The larger right lobe (segments V-VIII) 
and the smaller left liver lobe (segments I-IV). a: portal vein (blue), b: hepatic artery (red), c: bile duct 
(green), d: liver vein (fine, light blue), e: vena cava inferior (thick, light blue) (65). 
 
The portal vein collects blood from the unpaired abdominal organs and leads it to the 
liver. The blood of the portal vein contains sparse oxygen (venous), and is after a 
meal rich in nutrients (from the digestive organs) or in degradation products (e.g. 
bilirubin). This hepatic portal vein (vena portae) merges with the hepatic artery 
(oxygen-rich)  into the liver. 
The liver lobes are divided into smaller lobes with a maximal size of 1-2 mm. This 
smaller lobes appeare in cross sections as hexagonal arrangements and consist 
mainly of hepatocytes. In the corners of these hexagonal hepatocytes are located the 
periportal fields with the Glisson`s triangle (Fig. 6). The Glisson`s triangles consist of 
one branch of a hepatic artery (Arteria interlobularis), one branch of a portal vein 
(Vena interlobularis) and one branch of a bile duct (Ductus biliferus).  One branch of 
a hepatic artery and one branch of a portal vein are mixed and circulate to direction 
of the central vein. The central vein finally transports the blood into the vena cava 
inferior. Bile is derived from the bilecapillaries (Fig. 7). 
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Small bile duct (Ductus biliferus) 
 
Figure 6: Schematic cross section of a small liver lobe. In the corners of the hexagonal 
hepatocytes are located the periportal fields with the Glisson`s triangle. Red: hepatic artery, blue: 
portal vein, green: bile duct. 
 
Central vein
Hepatocyte
Branch of hepatic artery
Branch of portal vein
Small bile duct
Periportal field with 
Glisson`s triangle
 
Figure 7: Schematic magnified cross section of a small liver lobe. Magnified square of figure 6 
showing a periportal field in detail. One branch of a hepatic artery and one branch of a portal vein are 
mixed and flow to direction of the central vein. The central vein transports the blood into the vena cava 
inferior. Bile is derived from the bilecapillaries. 
 
The capillaries of the liver (the hepatic sinusoids) are located between the 
hepatocytes.This sinusoids are lined with windowed endothelial cells and contain the 
specific macrophages of the liver, the Kupffer cells (Fig. 8). The sinusoids transport 
the blood of the portal vein together with the blood of the hepatic artery through the 
hepatic lobules towards the lobule center, where the blood is received by a central 
vein (vena centralis). The space between the endothelial cells of the sinusoids and 
the hepatocytes is called the space of disse. In this space of disse the proper 
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detoxification takes place and further more the Ito cells (stellate cells) are arranged 
(Fig. 8).  
Hepatic Sinusoid Kupffer Cell
Stellate Cell
Space of Disse
Endothelial Cell
Hepatocyte
Nucleus
Tight junction
Stellate Cell
Space of Disse
Canaliculus 
 
Figure 8: Structure of hepatic sinusoids and hepatocytes. The hepatic sinusoids are lined with 
windowed endothelial cells (pink) and contain the liver specific macrophages, the Kupffer cells (green). 
The space between the endothelial cells of the sinusoids and the hepatocytes is called the space of 
disse. The stellate cells (blue) are arranged in the space of disse. The hepatocytes (violet) are 
connected among each other with bilechannels (canaliculus) and tight junctions. 
 
1.6 Function of the liver 
Besides its function of detoxification, the liver has a wide range of functions including 
protein synthesis (e.g. coagulation factors), storage and metabolism (e.g. glycogen 
storage and synthesis, decomposition of red blood cells, plasma protein synthesis, 
lipid metabolism, bile and hormone production). 
In the following two examples relevant for discussion are worked out in more detail:  
Glycogen synthase is a glycosyltransferase enzyme that catalyses the reaction of 
1,4-α-D-glucose to glycogen. Two isozymes of glycogen synthase are present in 
humans: 
Glycogen synthase 1 is expressed in muscle and other tissue, whereas expression of 
glycogen synthase 2 is restricted to hepatocytes.  
Liver glycogen serves as a storage pool to maintain the blood glucose level during 
fasting, whereas muscle glycogen functions as a stock to provide energy during 
activity.  
Phosphorylation of glycogen synthase decreases its activity, whereas 
dephosphorylation converts the enzyme in the fully active form (65).  
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Different protein kinases, especially the cAMP dependent Proteinkinase A (PKA) and 
the Glycogen synthase kinase 3 (GSK-3) phosphorylate serine and threonine 
residues of the glycogen synthase and this results in an inhibition of glycogen 
synthase.  
GSK-3 can be inhibited by Akt phosphorylation, which is part of the insulin signal 
transduction pathway. In consequence, phosphorylated GSK-3 (P-GSK-3) displays 
the inactive form of GSK-3 (66). 
 
Cytochrome P450 (CYP450) is a very large and diverse group of enzymes, 
consisting of 18 families and 43 subfamilies. Most of CYP450 enzymes are 
expressed in the liver. CYPs are the major enzymes involved in drug metabolism and 
bioactivation (e.g. monooxygenase reaction), accounting for approximately 75% of 
the total metabolism (67). Furthermore CYPs play important roles in steroid hormone 
synthesis (e.g. estrogen and testosterone), cholesterol synthesis and vitamin D 
metabolism. 
 
The liver is the first organ exposed to toxins from the gastrointestinal tract, for this 
reason, the liver holds the ability to regenerate and proliferate after damage or injury. 
 
1.7 The role of IL-6 signaling in liver regeneration 
To discriminate between the biologic function of human lL-6 (hIL-6) alone and that of 
the hlL-6/hslL-6R complex, Peters et al. generated double-transgenic mice 
coexpressing hlL-6 and hslL- 6R (hlL-6/ hslL-6R mice). The hlL-6/ hslL-6R mice were 
compared with hslL-6R and hlL-6 single transgenic mice and nontransgenic 
littermates. In hlL-6/ hslL-6R double transgenic mice were observed hepatocellular 
hyperplasia frequently surrounded by peliosis and necrosis, significant acceleration 
and aggravation of plasmacytoma formation, and excessive activation of 
extramedullary hematopoiesis in spleen and liver followed by a subsequent increase 
of all cellular components in the peripheral blood (68). IL-6 classic and Transsignaling 
seem to play a major role in liver proliferation.  
Excessive alcohol intake, drug overdose (e.g. paracetamol, tetracycline), fatty liver 
disease (FLD) and viral hepatitis can lead to potent liver damage. The liver has the 
unique capacity to regenerate after damage and injury. Only in the case of massive 
hepatic damage it leads to organ failure. Anyhow, liver failure is still a serious medical 
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problem and enhancing the potential of liver regeneration could be an effective and 
promising aim. 
Inhibition of hepatocellular apoptosis and necrosis and therewith enhancement of the 
endogenous potential for liver regeneration could be the basis for the prospective 
treatment of liver injury and organ failure. 
The important role of circulating proinflammatory cytokines like IL-1-beta, TNF-alpha 
and IL-6 has already been demonstrated (69). The role of IL-6 during liver 
regeneration has been extensively investigated and has established a critical role for 
IL-6 in mediating pro-mitotic and pro-survival activities within the regenerative 
process (70). 
 
The easiest stimulus for liver regeneration is the removal of liver tissue 
(hepatectomy). Thereafter the residual tissue is growing until the original mass is 
achieved. 
In liver research the model of two-thirds partial hepatectomy in rats was first 
pioneered by Higgins and Anderson (71) in 1931. In this model, two-thirds of the liver 
are surgically removed and the remaining liver enlarges in a hyperplastic response by 
replication of all residual hepatocytes of the liver. Once the liver has regained its 
original mass (5-7 days), proliferation stops (72). 
Adult hepatocytes are quiescent cells and rarely undergo cell division. They maintain 
the ability to proliferate in response to cell damage or loss of function (72), by 
undergoing one or two rounds of cell division and then return to their quiescent stage. 
Hepatocytes are resting in the G0 phase of the cell cycle. Gene activation (priming) is 
required for hepatocytes to enter into the G1 phase (Fig. 9). In early G1 phase, the 
cells fully respond to growth factors (e.g. HGF, TGFα) and then can progress through 
the cell cycle, overcome the G1 restriction point and undergo DNA replication. Tumor 
necrosis factor-α (TNF-α) and IL-6 where found in different studies (70, 73) to act as 
priming factors, inducing activation of NFĸB and STAT3. 
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Figure 9:  Multistep model of liver regeneration. Liver regeneration is divided into two phases, 
priming and cell cycle progression. Priming is a reversible process initiated by cytokines as well as 
nutritional and hormonal signals. Priming sensitizes the cells to growth factors but is ineffective in their 
absence. Growth factors are required for cells to move beyond a restriction point in G1. Expression of 
cyclin D1 signals the point in G1/S at which cells can progress to DNA replication independently of 
growth factors (74).  
 
IL-6 expression dramatically increases shortly following partial hepatectomy (75) and 
has been shown to mediate promitotic, pro-survival and anti-apoptotic responses to 
hepatocytes within the regenerative process (70, 76, 77). 
After partial hepatectomy were observed in IL-6 deficient mice a delayed hepatocyte 
mitotic response, as well as increased liver necrosis and mortality (70). In contrast to 
that finding, different groups published data concerning gp130 deficient mice, in 
which they observed only marginal effects on cell cycle and DNA synthesis after 
partial hepatectomy. This is leading to the notion that gp130-dependent signaling has 
no direct influence on cell cycle progression after partial hepatectomy but is relevant 
to activate protective pathways during hepatocyte proliferation (77).  
Because IL-6 plays a key role in acute-phase response which is taking place during 
liver injury, IL-6 can be identified as crucial factor during liver injury and regeneration. 
 
Treatment of mice with Hyper-IL-6 after partial hepatectomy resulted in an 
accelerated liver regeneration, which might be due to an observed decreased 
apoptosis and necrosis. These data indicate an important role of IL-6 Transsignaling 
during liver regeneration. The mechanism by which Hyper-IL-6 affects these 
regenerative process is still unknown (61, 78).  
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1.8 CCl4 induced liver damage 
There are various other animal models of liver damage simulating different human 
pathological conditions.  
Acute liver failure can be simulated by intraperitoneal D-galactosamine (D-Gal) 
treatment. D-Gal is an intracellular uridine depleting drug that blocks transcription and 
thereby causes acute liver damage (79). 
Concanavalin A (ConA) was used to study inflammatory liver disease. T-cell 
mediated hepatitis in mice can be induced by intravenous injection of the T-cell 
mitogenic plant lectin ConA (80). 
CCl4 can be used to mimic drug induced hepatoxicity. Paracetamol (acetaminophen) 
and ethanol are common liver damaging substances that are metabolized by a 
cytochrome P450 dependent monooxygenase to reactive metabolites (81).  
CCl4 is an organic compound, which was formerly widely used as refrigerant and as a 
cleaning agent. CCl4 is a hepatotoxin that, depending on the dosage, induces acute 
liver failure or chronic liver damage leading to fibrosis (82). 
CCl4 needs to be metabolized to induce liver damage. This metabolic activation is 
performed mainly by the enzyme Cyp450 2E1 in the endoplasmatic reticulum of 
hepatocytes. Through this reaction, the reactive CCl3•  and CCL3O2• radicals are 
formed which can covalently bind to proteins, lipids and nucleic acids and thus induce 
liver damage and initiate lipid peroxidation (82, 83) (Fig. 10).  
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Figure 10: Carbon tetrachloride (CCl4) and its metabolites. CCl4 is metabolized by cytochrome 
P450 2E1 into trichloromethyl-radical (CCl3• ) and trichloromethyl-peroxy-radical (CCL3O2•). 
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Lipid peroxidation in cell membranes occurs via reactive oxygen species (ROS), such 
as superoxide radical (O2•) and hydroxyl radical (OH-), and  can cause destruction of 
cell components and cell death (84).  
Recently, it has been shown that CCl4 not only causes primary liver necrosis, but also 
hepatocyte apoptosis (85). 
Inflammatory processes are involved in the development of CCl4-induced 
hepatotoxicity, in which Kupffer cells (the resident macrophages of the liver) secrete 
cytokines such as tumor necrosis factor-α (TNF-α), IL-1, IL-6 and IL-10 (86-91). In 
liver regeneration after CCl4 injury, TNF-α is important for hepatocyte proliferation, 
acting as a mitogen. CCl4-induced liver necrosis can be significantly ameliorated by 
treatment with anti-TNFα antibodies (88).  
In acute CCl4-induced liver damage, IL-6-/- mice reacted more sensitive to CCl4 than 
wild type mice. Serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels were higher in IL-6-/- mice as compared to WT mice 
and these livers showed less liver cell proliferation and more apoptosis. These effects 
could be reversed by previous IL-6 treatment (92). Katz et al demonstrated that IL-6-/- 
mice died in a dose-dependent manner 24–48 h after i.p. injections of CCl4, whereas 
WT mice were still viable. WT mice survived higher CCl4 dosages than IL-6-/- animals. 
Histological studies showed more necrotic areas in IL-6 knockout mice. Although IL-6 
injections failed to compensate this effect in IL-6 knockout animals, injecting Hyper-
IL-6 dose dependently increased survival rates (93). 
In contrast, chronical CCl4 treatment of IL-6 knockout mice showed reduced liver 
damage scores, lower aminotransferase levels and diminished apoptosis (94). 
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2 Aim of this study 
Interleukin-6 is known to play an important role in mediating pro-mitotic and pro-
survival activities within the regenerative liver process. 
The aim of the present study is to investigate the impact of IL-6 Transsignaling on 
liver damage and regeneration in a CCl4-based mouse model of acute drug-induced 
liver damage. In further experiments, only the effect of a total IL-6 blockade by using 
IL-6-/- mice or IL-6 neutralizing antibody, as well as artificially induced IL-6 
Transsignaling by Hyper-IL-6 have been analyzed. By blocking endogenous IL-6 
Transsignaling via sgp130 we demonstrate for the first time the importance of the sIL-
6R in response to chemically induced liver damage.  
Therefore C57/Bl6 mice were treated 18 h before CCl4-injection with soluble gp130Fc 
to block, or with Hyper-IL-6 to accelerate IL-6 Transsignaling.  
Subsequently parameters of liver damage and regeneration, e.g. alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) serum parameter, IL-6 
production, and induction of acute phase response were measured. 
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3 Material and Methods 
3.1 Material 
3.1.1 Chemicals 
All chemicals used were from ROTH, SIGMA or MERCK, unless otherwise stated. If it 
is not mentioned otherwise, deionized water (Millipore) was used as solvent. 
All molecular weight markers, DNA polymerases (Taq, Pfu, DreamTaq) and Reverse 
Transcriptase were obtained from MBI Fermentas (St. Leon-Rot, Germany). 
Oligonucleotides were ordered from Metabion (München, Germany).  
 
3.1.2 Animals 
Male C57Bl/6N were purchased from Charles River (Sulzfeld, Germany) and were 
maintained at a 12-hour light-dark cycle under standard conditions and provided with 
food and water ad libitum. For all experiments 4 – 6 mice per group were used. 
Transgenic homozygous sgp130 mice were generated and backcrossed to C57Bl/6N 
to generation 7 (64). Mice were bred at a 12-hour light-dark cycle under standard 
conditions and provided with food and water ad libitum. For blood flow cytometrie 
analysis 4 – 6 mice per group were used. 
sgp130Fc is expressed under the transcriptional control of the PEPCK promoter, 
which is mainly active in liver and kidney. Since the liver exhibits a high synthetic 
capacity, transgenic proteins driven by the PEPCK promoter have been shown to be 
secreted at high amounts into blood. 
 
3.1.3 Animal food 
The standard feed was obtained from SSNIFF Spezialdiäten GmbH (Soest, 
Germany).  
Standard :   
crude protein 19 % 
crude fat 3.30 % 
crude fibre 4.90 % 
crude ash 6.70 % 
Additives: Vitamin A: 15,000 IE/kg; Vitamin D3: 1,000 IE/kg; Vitamin E: 100 mg/kg; 
Cu: 5 mg/kg 
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3.1.4 Solutions and Buffers 
 
Immuno Blotting 
Blocking buffer   5 %    milk powder or BSA in TBS-T 
(Immuno blot) 
 
Transfer buffer   25 mM   Tris-HCl, pH 8.3 
(Immuno blot)   192 mM   glycine 
20 % (v/v)   methanol 
 
Lysis buffer   150 mM   NaCl 
(Tissue lysis)   2 mM    EDTA 
50 mM   Tris-HCl, pH 7.4 
1 % (w/v)   Triton X-100 
1 % (w/v)   NP-40 
1 mM    Na3VO4 
1 mM    NaF 
1 x    protease inhibitors 
 
Protease-inhibitors  COMPLETETM pills, Roche (Mannheim, Germany) 
Resuspending 1 pill in 50 ml Lysis buffer 
 
Running gel 10 % (15 %) 7.74 ml (4.5 ml)  deionized water 
(protein gels)   5.1 ml (5.1 ml)  1.5 M Tris, pH 8.8 
0.2 ml (0.2 ml)  10 %SDS 
6.6 ml (9.9 ml)  30 % Acrylamide-Bis  
0.2 ml (0.2 ml)  10 % APS 
0.02 ml (0.02 ml)  TEMED 
 
Stacking gel (4 %)  3.72 ml   deionized water 
(protein gels)   0.625 ml   0.5 M Tris-HCl, pH 6.8 
0.05 ml   10 % SDS 
0.67 ml   30 % Acrylamid-Bis  
25 µl    10 % APS 
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7 µl    TEMED 
 
SDS running buffer  25 mM   Tris-HCl, pH 8.3 
(protein gels)   192 mM   glycine 
0.1 % (w/v)   SDS 
 
Coomassie staining  40 % (v/v)   ethanol 
(protein gels)   10 % (v/v)   acetic acid 
0.1 % (w/v)   coomassie R250 
 
Destaining solution  10 % (v/v)   acetic acid 
(protein gels)   40 % (v/v)   methanol 
 
Sample-buffer (5x)  10 % (w/v)   SDS 
(protein gels)   5 % (w/v)   β-mercaptoethanol 
50 % (w/v)   glycerol 
0.13 % (w/v)  bromphenol blue 
300 mM   Tris-HCl, pH 6.8 
 
Sample-buffer (2x)  4 % (w/v)   SDS 
(protein gels)   20 % (w/v)   glycerol 
5 % (v/v)   β-mercaptoethanol 
0.13 % (w/v)  bromphenol blue 
125 mM   Tris-HCl, pH 6.8 
 
Stripping solution  0.5 M    NaCl 
(Immuno blot)   0.5 M    acetic acid 
 
Tris buffered saline  10 mM   Tris-HCl, pH 8.0 
(TBS     150 mM   NaCl 
Immuno blot)  
 
TBS-T    1 % (v/v)   Tween-20 in TBS 
(Immuno blot) 
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DNA Methods 
TBE (0.5x)    44.5 mM   boric-acid 
(agarose-gels)   10 mM   EDTA, pH 8.0 
44.5 mM   Tris-HCl 
 
DNA-sample buffer (5x)  20 % (w/v)   glycerol in TBE buffer 
(DNA-gels)    0.025 % (w/v)  bromphenol blue 
 
 
ELISA 
Phosphate buffered saline 150 mM   NaCl 
(PBS)    8 mM    Na2HPO4, pH 7.4 
1.7 mM   NaH2PO4, pH 7.4 
 
Washing buffer   0.05 % (v/v)   Tween-20 in PBS 
(PBS-T) 
 
Blocking buffer  1-5%   BSA in PBS-T 
(ELISA) 
 
Streptavidin solution 1:5,000  PBS-T 
(Strep-HRP, Roche) 
 
Stopping solution  1.8 M   H2O2 
(ELISA) 
 
FACS 
Blocking solution  0.5 µl   mouse or rat serum 
    0.5 µl   Fc-Receptor Block (BD Biosciences) 
    ad 10 µl  EDTA buffer 
 
EDTA buffer  2 mM   EDTA 
       in PBS 
       sterile filtrated 
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TBARS 
Thiobarbituric acid 67 mg   in 1ml DMSO + 9 ml H2O 
(TBA)       0.67 % (w/v) 
 
1,1,3,3-tetramethoxy 4.167 µl  in 1ml EtOH + 49 ml H2O 
propane (TMP)     (500 µM) 
 
Trichloroacetic acid 10 % (w/v)  in H2O ice cold 
 
 
Microsomal preparation 
Microsome buffer  10 mM  KH2PO4 
    0.25 M  Sucrose 
    1 mM   EDTA 
    0.1 % (w/v)  BSA 
    1 mM   DTT 
    pH 7.4 
 
 
3.1.5 Primary Antibodies  
Immuno Blotting 
anti-β-actin  rabbit polyclonal antibody which detects endogenous 
levels of human ß-actin (45 kDa), which showes species 
cross-reactivity with mouse (Cell signaling, Boston, USA). 
IB: dilution 1:1,000 (5 % BSA in TBS-T) 
 
anti-Phospho-  rabbit monoclonal antibody which detects endogenous  
STAT3  levels of rabbit STAT3 only when phosphoryated at 
tyrosine 705 (79, 86 kDa), which showes species cross-
reactivity with mouse (Cell signaling, Boston, USA). 
IB: dilution 1:2,000 (5 % BSA in TBS-T) 
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anti-STAT3 mouse monoclonal antibody which detects endogenous 
levels of total mouse STAT3 protein (79, 86 kDa) (Cell 
Signaling). 
IB: dilution 1:1,000 (5 % milk powder in TBS-T) 
 
anti-P450 2E1 rabbit polyclonal antibody which detects full length native 
rat cytochrome P450 2E1 (50-55 kDa), which showes 
species cross-reactivity with mouse. For usage in 
microsomal preparations, because of cellular localization 
in endoplasmatic reticulum membrane (abcam, 
Cambridge, UK). 
 IB: dilution 1:5,000 (5 % milk powder in TBS-T) 
 
anti-GSK-3ß mouse monoclonal antibody which detects endogenous 
levels of total mouse GSK-3ß protein (46 kDa) (BD 
Biosciences, Heidelberg, Germany). 
 IB: dilution 1:1,000 (3 % BSA in TBS-T) 
 
anti-Phospho- mouse monoclonal antibody which detects endogenous 
 GSK-3ß  levels of total mouse GSK-3ß (46 kDa) only when 
phosphorylated at tyrosine 216 (BD Biosciences, 
Heidelberg, Germany). 
IB: dilution 1:1,000 (3 % BSA in TBS-T) 
 
anti-caspase-8 mouse monoclonal antibody which detects endogenous 
levels of mouse full length caspase-8 (57 kDa), the 
cleaved intermediate p43/p41 and the caspase-8 active 
fragment p18 (Cell signaling). 
 IB: dilution 1:1,000 (5 % BSA in TBS-T) 
 
Animal treatment 
anti-Ly6G/Ly6C rat monoclonal antibody which reacts with a common 
mouse epitope on Ly-6G and Ly-6C, previously known as 
the myeloid differentiation antigen Gr-1. The antibody 
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recognizes granulocytes (neutrophils and eosinophils) and 
monocytes (BD Biosciences). 
 Treatment: 100 µg/ mouse i.p. 
 
anti-IL-6 Rat monoclonal antibody (MP5-20F3) reacts with mouse 
interleukin-6 (IL-6). The MP5-20F3 antibody is a 
neutralizing antibody (InVivo BioTech Services, 
Henningsdorf, Germany). 
 Treatment: 200 µg/mouse i.p. 
 
FACS 
Fc-Block   Mouse Fc Block CD 16/32 mAB (BD Biosciences) 
 
anti-Ly-6G/Ly-6C FITC Rat anti-mouse Ly-6G and Ly-6C (clone RB6-8C5) 
(BD Biosciences) reacts with a common epitope on Ly-6G 
and Ly-6C (Gr-1). 
FACS: dilution 1:400 
 
anti-CD11b PE Rat anti-mouse CD11b (Clone M1/70) (BD 
Biosciences) reacts with the 170 kDa α-chain of Mac-1 
(CD11b/CD18, αß2 integrin), also known as complement 
receptor 3 (CR3), which mediated adhesion to C3bi and 
ICAM-1 (CD54). Mac-1 is expressed on granulocytes, 
macrophages, myeloid-derived dendritic cells, natural killer 
cells, and B-1 cells. 
FACS: dilution 1:33 
 
anti-F4/80 APC Rat anti-mouse F4/80 antibody (clone BM8) 
(eBioscience, San Diego, USA) reacts with mouse F4/80 
antigen, an approximately 125 kDa transmembrane 
protein. The F4/80 antigen is expressed by a majority of 
mature macrophages. Other cell types such as 
Langerhans and Kupffer cells have been reported to 
express this antigen too. 
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 FACS: dilution 1:100 
 
anti-CD3 APC Hamster anti-mouse CD3 antibody (clone 145-2C11) 
(BD Biosciences) reacts with the 25 kDa ε chain of the T-
cell receptor-associated CD3 complex. 
 FACS: dilution 1:400  
 
Immunohistochemistry 
anti-neutrophil rat monoclonal antibody which detects a polymorphic 40 
kDa antigen expressed by mouse polymorphonuclear 
neutrophil cells, but absent on resident tissue 
macrophages (AbDserotec, Düsseldorf, Germany). 
 IHC: dilution 1:2,000 
 
anti-BrdU mouse monoclonal antibody which detects 5-bromo-2-
deoxyuridine (Vector Laboratories, CA). 
    IHC: dilution 1:50 
 
 
3.1.6 Secondary Antibodies 
All horseradish-coupled secondary antibodies were purchased from Amersham 
Bioscience (Buckinghamshire, United Kingdom) and used in a dilution of 1:5,000. 
 
3.1.7 Recombinant cytokines 
human IL-6  kindly provided by Steffi Schnell and Annett Kaßner 
(Biochemical Department, University of Kiel); was 
prepared and purified as described in (95). 
 
Hyper-IL-6  The fusion protein of the human IL-6 and the human IL-
6R, Hyper-IL-6 ; kindly provided by Steffi Schnell and 
Annett Kaßner (Biochemical Department, University of 
Kiel), was  prepared and purified as described in (58). 
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sgp130-Fc  kindly provided by Steffi Schnell and Annett Kaßner 
(Biochemical Department, University of Kiel); was 
prepared and purified as described in (63). 
 
 
3.2 Molecular biology methods 
3.2.1 DNA Gelelectrophoresis 
DNA fragments were separated by horizontal electrophoresis cambers (BioRad) 
using agarose gels. Agarose gels were prepared by heating 1-2 % (w/v) agarose 
(Biozym) in 0.5 x TBE buffer, depending on the size of the DNA fragments, and the 
gels were supplemented with 0.05 % ethidium bromide. The samples were mixed 
with an appropriate amount of 6 x DNA sample buffer and loaded on the agarose gel. 
The gels were run at constant voltage (100 V) and finally documented using the Gel 
Doc 2000 UV-light documentation system (BioRad). 
 
3.2.2 RNA Isolation 
Total RNA from liver tissue was isolated using the NucleoSpin RNA II Kit (Macherey-
Nagel) according to the manufacturer`s instructions. RNA concentration was 
determined by UV-spectrophotometry using the NanoDrop ND-1000 (peqLab 
Biotechnologie GmbH). 2 µg of isolated total RNA was used as template for the RT-
PCR reaction, as further described in 3.2.4. 
 
3.2.3 Polymerase chain reaction (PCR) 
A ß-actin DNA fragment was PCR-amplified using an Eppendorf PCR-cycler in a total 
volume of 20 µl. The enzyme DreamTaq-polymerase as well as the appropriate 
buffers were obtained from MBI Fermentas. The following reaction mixture was used:  
 
PCR-buffer (10x)    2.5 µl 
Nucleotides (dNTPs)   10 mM each 
Forward-primer    10 pmol (appendix) 
Reverse-primer    10 pmol (appendix) 
DreamTaq-polymerase   1 U 
ddH2O     add 20 µl 
Template     2 ng 
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The PCR was performed using the following thermal cycling : 
 
95°C   3 min     initial denaturation step 
57°C  50 sec 1 x  primer annealing 
72°C  50 sec   elongation 
95°C   40 sec    denaturation 
57°C   50 sec 33 x    primer annealing 
72°C   50 sec   elongation  
72°C   2 min   1 x  final elongation step 
 
3.2.4 Reverse transcription PCR (RT-PCR) 
RT-PCR is a PCR amplification of a product from the reverse transcription (RT) 
reaction, whereby a template mRNA is translated into a single-stranded cDNA. 
RevertAid M-MuLV Reverse Transcriptase from Fermentas was applied according to 
the manufacturer`s instructions. The reactions were performed using oligo (dT) 
primer annealing the 3’ poly(A) mRNA tail. The PCR settings were described above. 
The following reaction mixture was used: 
 
RNA     2 µg 
Oligo (dT)    0.5 µg 
ddH2O    add 11.5 µl 
 
The mixture was heated at 70°C for 5 min and then cooled on ice. The following 
components were subsequently added: 
 
Reaction buffer (5x)  4 µl 
dNTPs    20 mM each 
RevertAid M-MuLV RT  1 µl 
ddH2O    add 20 µl 
 
The reaction mix was incubated for 1 hour at 42°C. Afterwards the Reverse 
Transcriptase was heat inactivated at 70°C for 10 min. The mixture was filled add 
100 µl with ddH2O. 1 µl of the resulting cDNA was used directly for the subsequent 
PCR. 
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3.2.5 Quantitative polymerase chain reaction (Real Time PCR) 
After RNA extraction and processing, TaqMan-based “gene expression assays” for 
β2-microglobulin (Mm00437762_m1), SAA1 (Mm00656927_g1), SAA3 
(Mm00441203_m1), GSK-3ß (Mm00444911_m1) and Haptoglobin 
(Mm00516884_m1) were performed. All primers were bought at Applied biosystems 
(ABI, Foster City, CA). Reactions were performed on an ABI-Prism/7000 Sequence 
Detection System (ABI). Primers for ß2-microglobulin are binding around exon 1-2 
boundary, for SAA1 around exon 3 - 4 boundary, for SAA3 around exon 2-3 
boundary, for GSK-3ß around exon 8-9 boundary and for haptoglobin around exon 4 
- 5 boundary. All data were analyzed in duplicates. mRNA Expression levels were 
normalized to ß2-microglobulin expression. The expression level of solvent treated 
C57Bl/6 mice was set to 1. All other values are given as fold control of expression in 
solvent control animals.  
 
3.2.6 Protein preparation and concentration (BCA) 
Protein extracts were prepared from tissue samples (~100 mg) by homogenization in 
500 µl cell lysis buffer. The protein concentration was determined using the BCA kit  
according to the manufacturer`s instructions (Pierce). The extinction was determined 
at 568 nm in a microtiter plate reader (Tecan, Maennedorf, Switzerland). 
 
3.2.7 SDS-polyacrylamide gel electrophoresis 
Separation of proteins was performed with a discontinuous SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Mini-Protean III system (BioRad).  
After complete polymerization of the gel, the chamber was assembled as described 
by the manufactures protocol. Up to 30 µl sample were loaded in the pockets and the 
gel was run at constant voltage (120 V) until entry into stacking gel, when voltage 
was rised to 180 V for the remainder. The gel run was stopped when the bromphenol 
blue line reached the end of the gel. Gels were then either stained with coomassie or 
transferred to PVDF membrane and immuno blotting was performed. 
 
3.2.8 Immuno Blot analysis 
Proteins were transferred from the SDS-gel on a PVDF membrane (GE Healthcare, 
Uppsala, Sweden) using a MINI TRANSBLOT-apparatus (BioRad Laboratories 
GmbH, Munich, Germany). The blotting sandwich was assembled as described in the 
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manufactures protocol. Proteins were transferred electrophoretically at 4°C in 
Blotting-buffer at constant voltage (90 V, 120 min). 
After electrophoretic transfer, the membranes were removed from the sandwiches 
and placed with the protein-bound side up in a 50 ml falcon. Membranes were 
immediately incubated with 20 ml blocking buffer for 1 hour at RT. Afterwards, the 
primary antibody was added in the apropriate dilution overnight at 4°C. The primary 
antibody was removed by washing the membrane 3 times for 10 min with TBS-T. The 
corresponding secondary antibody was applied for 1 hour at RT in TBS-T/ 4% milk 
powder in dark. Afterwards the membrane was washed again 3 times for 10 min with 
TBS-T and developed using the ECL-Plus Western blotting Detection System (GE 
Healthcare). The signals were visualized by X-ray film (GE Healthcare) in darkroom 
or with the chemiluminescence kamara system LAS-1000 (Fujifilm, USA) for defined 
time periods. 
 
3.2.9 TBARS quantification 
Thiobarbituric acid reactive substances (TBARS) were used as an index of of lipid 
peroxidation and oxidative stress. Thiobarbituric acid (TBA) forms under high 
temperatures adducts with the lipid peroxidation product malondialdehyde (MDA), 
which can be measured at 532 nm. 1 mg liver tissue homogenate (100 µl) was mixed 
with 200 µl ice cold 10% (w/v) trichloroacetic acid to precipitate proteins. After 
incubation (15 min on ice) and centrifugation (2,200 x g, 15 min, 4°C) 200 µl of the 
supernatant was mixed with an equal volume TBA (Merck, Darmstadt, Germany) and 
incubated for 10 min at 100°C. After cooling, the formed TBA-MDA-adduct was 
measured colorimetrically at 532 nm in triplicates using TMP (1,1,3,3-
tetramethoxypropane, Sigma-Aldrich, Steinheim, Germany) as standard (Tecan 
Reader, Maennedorf, Switzerland). 
 
3.2.10 Enzyme-linked immunosorbent Assay (ELISA) 
To determine the concentration of different antigens the “sandwich” ELISA method 
was used. First, the capture antibody was coated to a microtitre plate (Greiner 
Microlon, Solingen, Germany). After blocking, antigen was added and allowed to 
complex with the bound antibody. Unbound products were removed by extensive 
washing, and a biotinylated detection antibody was added. Finally subsequent 
addition of streptavidin-horseradish peroxidase (Roche, Mannheim, Germany) and 
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peroxidase substrate (Roche, Mannheim, Germany) led to a calorimetric reaction 
which allowed the quantitation by measuring the amount of bound detection antibody. 
To determine the absolute amount of antigen in the samples a purified antigen 
standard was used. The following general protocol was used:  
50 µl of coating antibody-solution was added to each well and incubated at RT over 
night; the wells were washed three times with 300 µl PBS-T; 200 µl of blocking buffer 
was added to saturate the remaining protein binding sites on the microtiter plate for 1 
hour at room temperature; the wells were washed three times with 300 µl PBS-T. The 
samples (mostly plasma or liver homogenate) were diluted in PBS supplemented with 
1 % BSA and 50 µl of diluted sample or purified antigen standard were added to each 
well for 2 hours at RT.  
Thereafter the wells were washed three times with PBS-T and 50 µl of detection 
antidody solution was added to each well and incubated at RT for 2 hours. The wells 
were washed three times with PBS-T and 100 µl of streptavidin-horseradish 
peroxidase solution (1:5,000 in PBS supplemented with 1 % BSA) was added and 
incubated for 45 min at RT. The wells were again washed three times with PBS-T 
and 75 µl of the peroxidase substrate BM blue POD (Roche) was added for 
approximately 20 min and the reaction was stopped by addition of 75 µl stopping 
solution. The optical densities at 450 nm were measured on an ELISA plate reader 
(SLT Rainbow; Tecan, Maennedorf, Switzerland). 
The human gp130 ELISA kit, the murine IL-6R ELISA kit,  as well as the murine IL-6 
ELISA kit were purchased from R&D systems and were used according to the 
manufactures protocol. 
 
3.2.11 Statistical analysis 
Data are expressed as mean values ± SD; 4-6 mice were used per experimental 
group. Statistical analysis was performed by using a Student’s unpaired t test 
(GraphPad InStat version 3.0, GraphPad Software, San Diego California USA). A p-
value below 0.05 was considered statistically significant (* P<  0.05; ** P <  0.01; *** 
P <  0.001). 
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3.3 Animal Methods 
3.3.1 CCl4 induced liver damage 
Male C57Bl/6N mice were kept at a 12-hour light-dark cycle under standard 
conditions and provided with food and water ad libitum. For all experiments 4 – 6 
mice per group were used. Liver damage was induced by a single intraperitoneal 
injection of CCl4 (Sigma, Deisenhofen, Germany) dissolved in rape oil immediately 
before treatment and applied as one dose of 3 ml/kg body weight. All experiments 
were performed according to the German guidelines for animal care and protection 
(V 31272241.121-3 (41-3/06)). 
 
3.3.2 Blockade of IL-6 Transsignaling with sgp130Fc 
Mice were treated i.p. with 250 µg sgp130Fc 18 h prior to CCl4 treatment. sgp130Fc 
levels were measured via Enzyme-linked immunoabsorbent assays in the serum of 
the mice as described (Rabe and others 2008) using a human gp130 Elisa Kit 
(DuoSet human gp130 ELISA Kit, R&D Systems, Wiesbaden, Germany) according to 
the manufacturers’ instructions. Serum was diluted 1:2,000 in 1% BSA/PBS and 
measured in duplicates. Recombinant gp130 was used as standard. 
 
3.3.3 Enhancement of IL-6 Transsignaling with Hyper-IL-6 
10-12 weeks old male C57/Bl6 mice were treated with 4 µg Hyper-IL-6 i.p. 18 hours 
prior to CCl4 treatment. 
 
3.3.4 Neutrophil depletion 
As described previously (64), neutrophils were depleted using a purified rat anti-
mouseLy6G/Ly6C monoclonal antibody (mAb) (BD Bioscience, Heidelberg, 
Germany). Mice were injected with 100 µg mAb i.p. 18 h prior to CCl4. Depletion was 
controlled with stainings of neutrophils on paraffin tissue sections as described 
below. 
 
3.3.5 Blockade of IL-6 Signaling 
Circulating IL-6 was depleted by using a purified monoclonal anti-IL-6 Antibody. Mice 
were injected with 200 µg antibody i.p. 18 hours prior to CCl4. Mice were sacrificed at 
different timepoints after CCl4 treatment and liver and blood samples were taken. To 
control for depletion, IL-6 ELISA on serum samples was used as described above. 
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3.3.6 Plasma/ Serum preparation of whole mouse blood 
Whole mouse blood was collected either by tail bleeding or cardiac puncture. Tubes 
for taking blood (Sarstedt, Nümbrecht, Germany) were coated with Lithium-Heparin 
to prevent clotting. Plasma was obtained by centrifugation (5 min, 10,000 rpm, 4°C) 
and stored at –20°C. 
Serum was obtained by collecting whole mouse blood in not-coated tubes and led it 
coagulate for 1-2 hours at 4°C. Afterwards serum was obtained by centrifugation (5 
min, 10,000 rpm, 4°C) and stored at –20°C. 
 
3.3.7 Serum parameter 
Serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), 
potassium and uric acid were determined in diluted blood serum using a Reflotron 
analyzer (Roche Diagnostics, Basel, Switzerland) and Reflotron test strips. Blood 
glucose levels were measured using a OneTouch Ultra device (LifeScan, 
Neckargemünd, Germany). Mouse whole blood was used for analysis.  
 
3.3.8 Flow cytometry analysis of mouse blood 
To analyze the number of neutrophils in mouse blood flow cytometry analysis was 
performed. 
For this, 20 µl blood was collected from mouse tail, immediately transferred into 100 
µl FACS EDTA buffer to prevent clotting and inverted briefly. For each staining 100 µl 
of blood/ EDTA buffer mixture was tranferred into a well of a 96-well-plate. One 
additional sample was necessary for each individual staining antibody and one for a 
negative staining control. 
The samples were blocked with 10 µl FACS blocking solution and icubated 5 min on 
ice. Afterwards staining mastermix was prepared: 
 
FITC Ly6G:  0.25 µl/ sample 
PE CD11b:  3 µl/ sample 
APC F480:  1 µl/sample 
 
For individual stainings FITC Ly6G 0.25 µl, PE CD11b 3 µl and APC CD3 0.25 µl 
were used. 
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All stainings were incubated for 30 min in the dark at 4°C. Thereafter 96-well-plate 
was centrifuged at 1,500 rpm for 5 min at 4°C, supernatant was discarded and pellet 
was immediately resuspend in 100 µl 1 x FACS Lysing solution (BD Biosciences). 
Samples were incubated for 10 min in the dark at RT and centrifuged again (1,500 
rpm, 5 min, 4°C). Supernatant was discarded and pellet was again resuspend in 100 
µl 1 x FACS Lysing solution (BD Biosciences) and incubated for 5 min (in the dark, 
RT). After centrifugation (1,500 rpm, 5 min, 4°C) supernatant was discarded, pellet 
was resuspend in 200 µl PBS and immediately transferred into FACS-tubes 
(Sarstedt) for analyzing in flow cytometry (FACS-Canto; Becton Dickinson, 
Heidelberg, Germany). 
 
3.3.9 BrdU Labeling 
BrdU (5-bromo-2-deoxyuridine) is a synthetic nucleoside that is an analogue of 
thymidine and provides a simple technique for labeling and identifying proliferating 
cells. BrdU can be incorporated into the newly synthesized DNA of replicating cells 
(during the S-phase of the cell cycle), substituting for thymidine during DNA 
replication. Antibodies specific for BrdU can then be used to detect the incorporated 
chemical, thus indicating cells that were actively replicating. 
Two hours prior to sacrificing, mice were injected with 10 µl/µg body weight BrdU. 
Positive cells were visualized immunhistochemically and representative pictures were 
given. 
 
3.3.10 Histological and immunohistochemical analysis 
Liver samples were handled as indicated below: 
     
4 % Formaldehyde   over night, 4°C 
H2O     5 hours 
70 % EtOH    over night, RT 
96 % EtOH I    30 min 
96 % EtOH II   60 min 
100 % EtOH I   60 min 
100 % EtOH II   30 min 
Xylol I     90 min 
Xylol II    90 min 
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Paraffin I    30 min 
Paraffin II    over night 
Paraffin III    60 min 
 
 
HE staining 
Tissue sections were shortly incubated in Gill3 Hematoxylin (Thermo Scientific, 
Cheshire, UK), differentiated in 0.5% acetic acid, rinsed in tap water and 
counterstained with Giemsa’s azur eosin methylene blue solution (Merck, Darmstadt, 
Germany). Necrotic areas were quantified using ImageJ-Software. Necrotic areas 
were calculated from 30 random highpowered fields of three mice and given in 
percent of total area. 
 
DAPI staining 
Tissue sections were stained with DAPI (4’,6-Diamidino-2-phenylindole 
dihydrochloride) (Sigma, Deisenhofen, Germany) at 0.1 µg/ml PBS. 
 
Periodic Acidic Schiff (PAS) staining  
Glycogen was stained within the liver with PAS stainings as described previously 
(Drucker et al.). Shortly, tissue sections were incubated in 0.8 % periodic acid 
(Sigma, Deisenhofen, Germany) followed by an incubation in Schiff´s reagent 
(Sigma, Deisenhofen, Germany). Sections were counterstained with Shandon Gill3 
Hematoxylin (Thermo Scientific, Cheshire, UK). 
 
Neutrophil staining 
Staining for neutrophils was carried out using a monoclonal rat anti-mouse Neutrophil 
Antibody  (AbDserotec, Düsseldorf, Germany) diluted in sample diluent (Dako, 
Glostrup, Denmark). After incubation with biotinylated polyclonal rabbit anti-rat 
antibody (Dako, Glostrup, Denmark) and EnVision-HRP (Dako, Glostrup, Denmark) 
the signal was developed with AEC Substrate (Dako, Glostrup, Denmark). Samples 
were counterstained with Shandon Gill3 Hematoxylin (Thermo Scientific, Cheshire, 
UK).  
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5-bromo-2-deoxyuridine (BrdU) staining 
Staining for BrdU was carried out using a mouse monoclonal BrdU Antibody  (Vector 
Laboratories, CA) diluted in sample diluent (Dako, Glostrup, Denmark). After 
incubation with labeled polymer-HRP-anti-mouse antibody (Dako envision, Glostrup, 
Denmark), the signal was developed with AEC Substrate (Dako, Glostrup, Denmark). 
Samples were counterstained with Shandon Gill3 Hematoxylin (Thermo Scientific, 
Cheshire, UK).  
 
Tunel staining 
Staining for Apoptosis was carried out using a Peroxidase in Situ Apoptosis Detection 
Kit (Chemicon International, Billerica, USA). The signal was developed with DAB 
Substrate (3,3' Diaminobenzidine, Dako, Glostrup, Denmark) and samples were 
counterstained with methylgreen (Serva, Heidelberg, Germany).  
 
 
3.3.11 Preparation of Microsomes 
Mice livers were homogenized in 10 mM KH2PO4, pH 7.4, containing 0.25 M sucrose, 
1 mM EDTA, 0.1% (w/v) BSA and 1 mM DTT at 4°C. The homogenate was 
centrifuged at 750 x g for 15 min and the supernatant was again centrifuged until the 
pellet remained pale (normally 3-5 centifugation steps). The pellet was discarded. 
Subsequently the supernatant was centrifuged at 10,300 x g for 20 min. The pellet 
was discarded and the supernatant was centrifuged at 137,000 x g for 70 min. The 
supernatant was discarded and the pellet was resuspended in buffer and centrifuged 
again at 137,000 x g for 70 min. The final pellet was resuspended in buffer and 
stored at –80°C. Samples were taken for measuring protein concentration using the 
BCA Kit (Pierce, Rockford, IL). Equal amounts of protein were analyzed with immuno 
blotting analysis using a polyclonal CYP2E1 Ab (Abcam, Cambridge, UK) as 
described above. 
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3.4 Primers and Markers 
DNA-Ladder 
 
Figure 3.4.1: 1 kb DNA-Ladder from Fermentas. 
 
Protein-Ladder 
A          B 
 
Figure 3.4.2: Protein Molecular Markers (Fermentas). (A) Prestained Protein Molecular Marker (20-
120 kDa) from Fermentas. (B) Protein Molecular Weight Marker (14,4-116 kDa) for Coomassie- or 
silverstaining from Fermentas. 
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4 Results 
4.1 Identifying the critical dosis of CCl4 by using different 
concentrations 
Acute liver damage was induced with a single injection of CCl4. Liver damage was 
quantified by measuring serum alanine aminotransferase (ALT), aspartate 
transferase (AST) levels, blood glucose levels, as well as histological evaluation via 
HE-stainings.  
ALT catalyzes the transfer of an amino group from alanine to a-ketoglutarate. Usually 
ALT is detectable in high concentration within hepatocytes. In case of hepatic 
damage, ALT is found in the sera. 
AST catalyzes the conversion of aspartate and alpha-ketoglutarate to oxaloacetate 
and glutamate, and vice-versa. Serum levels are raised in acute liver damage. As it is 
also present in red blood cells, cardiac muscle, skeletal muscle, kidney and brain 
tissue, elevated serum levels might be as well due to damage to those tissue. 
In the first instance, a CCl4 concentration to study effects of IL-6 Transsignaling on 
CCl4 induced liver damage should be determined. 
 
In the beginning, C57Bl/6N mice were treated with 3 ml/kg body weight CCl4 to 
induce an acute liver damage. Blood samples were taken direct, 24 and 48 hours 
after CCl4 injection. ELISA for soluble IL-6Receptor (sIL-6R) was carried out and 
revealed significant elevated sIL-6R levels in the sera of CCl4 treated mice when 
compared to mock treated mice (P< 0.005) (Fig. 4.1.1). To investigate the effect of IL-
6 Transsignaling to CCl4 induced liver damage, IL-6 Transsignaling should be 
modulated by either blocking via sgp130Fc or accelerating via Hyper-IL-6. 
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Figure 4.1.1: Soluble IL-6R levels after CCl4 injection. C57Bl/6N mice were treated with 3 ml/kg 
body weight CCl4. sIL-6R ELISA in mouse sera was performed at the indicated timepoints. A 
significant increase of sIL-6R was detected after CCl4 injection. Unpaired student`s t test: ** P< 0.005; 
***P< 0.0001. 
 
10-12 weeks old male C57/Bl6N were injected intraperitoneally (i.p.) with 1, 3 and 8 
ml CCl4 per kg body weight dissolved in rape-oil. Mice were treated with 250 µg 
sgp130Fc i.p. to block IL-6 Transsignaling, 4 µg Hyper-IL-6 i.p. to accelerate IL-6 
Transsignaling, or mock treatment 18 hours prior to CCl4 intoxication. 
In mice treated with 1 ml CCl4/ kg body weight were obtained 48 hours after CCl4 
induced liver damage elevated ALT and AST serum levels. Animals pretreated with 
sgp130Fc developed slightly increased ALT and AST levels when compared to CCl4 
only or Hyper-IL-6 pretreated mice (Fig. 4.1.2A).  
In mice treated with 3 ml CCl4/ kg body weight were obtained higher ALT and AST 
serum levels, which were significantly increased in mice with blocked IL-6 
Transsignaling via sgp130Fc (Fig. 4.1.2B).  
In mice treated with 8 ml CCl4/ kg body weight were observed no differences 
between CCl4 only, sgp130Fc pretreated or Hyper-IL-6 pretreated groups (Fig. 
4.1.2C). 
48 hours after intoxication blood glucose levels were slightly reduced in all CCl4 
treated mice (100-150 mg/dl) in comparison to mock treated mice (200 mg/dl) with no 
differences between the pretreated groups (Fig. 4.1.3). Modulating IL-6 signaling 
however had no effect on glucose levels. 
HE stainings of liver sections revealed increased damage around central veins of 
mice treated with CCl4. When the CCl4 dosage was elevated, also the extent of liver 
damage increased (Fig. 4.1.4).  
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Figure 4.1.2: Measurement of ALT and AST serum levels. C57Bl/6N mice were treated with 1 (A), 
3 (B) and 8 (C) ml/kg body weight CCl4 after previous injection of sgp130Fc, Hyper-IL-6 or mock 
treatment. ALT and AST serum levels were measured 48 hours after setting the liver damage. 
Unpaired student`s t test: * P< 0.05; ** P< 0.005. 
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Figure 4.1.3: Measurement of blood glucose levels. C57Bl/6N mice were treated with 1 (A), 3 (B) 
and 8 (C) ml/kg body weight CCl4 after previous injection of PBS (black bars), sgp130Fc (grey bars), 
Hyper-IL-6 (striped bars) or mock treatment (white bars). Glucose levels from whole blood revealed a 
slight reduction in all CCl4 treated groups with no differences between the groups. 
 
 
A     B     C   
 
Figure 4.1.4: HE staining of a CCl4 intoxicated liver. Hematoxylin /Eosin stainings of liver sections 
48 hours after CCl4 treatment in 20 fold magnification. C57/Bl6N mice were treated with 1 (A), 3 (B) 
and 8 (C) ml/kg body weight CCl4 i.p. Livers showed increasing damage around central veins with 
increasing  CCl4 dosage. 
 
 
4.2 Blockade of IL-6 Transsignaling via sgp130Fc 
To specifically block IL-6 Transsignaling, mice were injected with 250 µg sgp130Fc 
i.p. 18 hours before CCl4 treatment. Serum levels at the time of sacrificing showed 
that sgp130Fc levels were around 55 pg/ml 6 hours after CCl4 treatment, and 
decreased slowly within the course of experiment to around 35 pg/ml (Fig 4.2.1).  
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Figure 4.2.1: Serum sgp130Fc levels. C57Bl/6 mice were injected with 250 µg /mouse i.p. 18 hours 
before CCl4 intoxication. Serum sgp130Fc levels were measured via ELISA at the indicated time 
points. The protein was relatively stable and showed a slight reduction within the duration of the 
experiment. 
 
 
4.3 Quantification of CCl4-induced liver damage 
In all following experiments 10-12 weeks old male C57/Bl6N mice were injected 
intraperitoneally with 3 ml CCl4 per kg body weight dissolved in rape-oil. Mice were 
pretreated with PBS i.p., 250 µg sgp130Fc i.p., 4 µg Hyper-IL-6 i.p., or mock 
treatment 18 hours prior to CCl4 intoxication. 
Mice were sacrificed at different time points between 6 and 48 hours post injection. 
For analyzing the acute phase response, mice were sacrificed 0, 2, 4 and 6 hours 
after CCl4 intoxication. 
 
4.3.1 ALT and AST serum levels 
ALT and AST values were elevated after CCl4 treatment at all time points in 
comparison to mock treated control animals.  
6 hours after CCl4 intoxication ALT levels reached values around 1,000 U/L with no 
significant differences between the CCl4 treated groups. Serum levels of mock 
treated mice achieved ALT serum levels of 400 U/L.  
AST serum levels of CCl4 treated mice were elevated to around 1,700 U/L, while IL-6 
Transsignaling blocked mice showed slightly increased values of about 2,500 U/L. 
Activating of IL-6 Transsignaling showed a little decrease in AST levels 6 hours after 
CCl4 treatment to values around 1,000 U/L. Control animals revealed AST values of 
around 500 U/L. 
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24 hours after the intoxication ALT and AST values were strongly elvated in all 
groups compared to control animals. 
CCl4 treatment led to ALT levels of about 4,000 U/L. When IL-6 Transsignaling was 
blocked, ALT levels increased significantly to 12,000 U/L (P< 0.0001). When IL-6 
Transsignaling was activated by Hyper-IL-6, ALT levels reached values around 5,000 
U/L, which was a significant reduction compared to sgp130Fc pretreated mice (P< 
0.0001), but had no obvious protective effect compared to only CCl4 treated mice.  
The same tendencies were observed in AST measurements. AST levels were clearly 
elevated over solvent controls in all groups. AST levels of CCl4 treated animals 
reached values about 10,000U/l. When IL-6 Transsignaling was blocked, AST levels 
increased significantly to about 27,000 U/L (P< 0.05). Activating IL-6 Transsignaling 
by Hyper-IL-6 led to AST levels of about 15,000 U/L, which was a significant 
reduction compared to blocked IL-6 Transsignaling (P< 0.05). As observed in ALT 
levels, there was no protective effect of Hyper-IL-6 treatment notable. 
48 hours post-injection of CCl4, serum transferase levels continued to increase. 
Hyper-IL-6 pretreatment led to decreased ALT and AST levels, whereas sgp130Fc 
treatment led to significantly increased levels (Fig. 4.3.1). 
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Figure 4.3.1: Measurement of ALT and AST serum levels. C57Bl/6N mice were treated with CCl4 
after previous injection of PBS, sgp130Fc, Hyper-IL-6 or mock treatment. ALT (A) and AST (B) serum 
levels were measured at the indicated time points. Serum levels were significantly elvated when mice 
were pretreated with sgp130 24 and 48 hours after the damage. Unpaired student`s t test: * P< 0.05; 
** P< 0.005; ***P< 0.0001. 
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4.3.2 Blood glucose levels 
CCl4 injection led to a decrease in blood glucose levels after 24 to 48 hours (100-120 
mg/dl) compared to mock treated control mice (220-250 mg/dl). There was no 
significant difference detectable between the different treated mouse groups (Fig. 
4.3.2). 
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Figure 4.3.2: Blood glucose levels after CCl4 intoxication. Blood glucose levels were measured at 
the indicated time points. In comparison to mock control animals, blood glucose levels were lower but 
showed no differences between the different pre-treatment groups. 
 
 
4.3.3 HE and DAPI stainings 
Livers of mice 48 hours after CCl4 treatment were first fixed in formaldehyde, 
dehydrated in alcohol and afterwards embedded in paraffin. Hematoxylin/Eosin 
stainings were performed to give an overview about the architecture and the extent of 
damaged regions and intact areals. Histological examination of the overall liver 
damage 48 h after CCl4 administration showed smaller necrotic areas in CCl4 treated 
mice compared to sgp130Fc pretreated mice (Fig. 4.3.3 a, b, c, d). Quantification of 
liver damage 48 h after CCl4-induced liver damage indicated that only 33.2% of the 
liver was necrotic in CCl4 treated mice compared to 58,6% in sgp130Fc pretreated 
mice (Fig. 4.3.4 B). No significant difference was seen in the number of apoptotic 
nuclei as measured by TUNEL staining (Fig. 4.3.3 e, f). Using DAPI staining, we 
noted less intact nuclei and extended necrotic areas in sgp130Fc pretreated animals 
(g, h). The reduction of DAPI positive hepatocytes is shown in Fig. 4.3.4 A.  
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Figure 4.3.3: Histological evaluations of liver sections 48 hours after CCl4 injection. (a) 
Hematoxylin Eosin stainings (10 fold magnification) of CCl4 only and (b) of sgp130Fc pretreated mice, 
(c) Hematoxylin Eosin stainings (20 fold magnification) of CCl4 only and (d) of sgp130Fc pretreated 
mice, (e) Tunel stainings (20 fold magnification) of CCl4 only and (f) of sgp130Fc pretreated mice, (g) 
DAPI stainings (40 fold magnification) of CCl4 only and (h) of sgp130Fc pretreated mice. Damage is 
more severe in sgp130 pretreated animals, but the occurrence of apoptotic events are comparable.  
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Figure 4.3.4: Quantification of liver damage. (A) Quantification of DAPI stainings show that more 
nuclei are intact in CCl4 treated animals in comparison to sgp130Fc pretreated animals (P< 0.0001). 
(B) Quantification of HE stainings show more necrotic area in sgp130Fc pretreated mice (P< 0.005) 
when compared to CCl4 treated mice. 
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4.3.4 Uric acid and potassium serum level 
To further quantify cell damage, uric acid and potassium levels in blood serum were 
measured.  
Uric acid plays a protective role in defending organs and tissues from oxidative 
damage by attenuating oxidation of plasma lipids, lipoproteins and unsaturated fatty 
acids. There has been identified a critical role for uric acid in antioxident defense and 
lipid peroxidation in human blood plasma (96-99). 
48 hours after CCl4 treatment, uric acid levels increased in blood serum. In sgp130Fc 
pretreated mice uric acid serum level reached values about 15 mg/dl, which was 
significantly higher when compared to CCl4 only treated animals, where values 
reached around 7 mg/dl (P< 0.05). In Hyper-IL-6 pretreated mice uric acid levels only 
reached levels of around 3 mg/dl, which was significantly less than in sgp130Fc 
pretreated (P< 0.005) and in CCl4 only treated mice (P< 0.05) (Fig. 4.3.5A). 
Also potassium levels increased to higher values in sgp130Fc pre-treated animals. 
Values reached levels of around 20 mval/L, whereas Hyper-IL-6 pretreated and CCl4 
only treated mice reached values of about 14 mval/L (Fig. 4.3.5B).  
This indicates that cell damage is higher when IL-6 Transsignaling is blocked. We 
conclude from this findings that there has to be components specifically activated 
under the blockade of IL-6 Transsignaling which are responsible for an enhanced 
damage, or that protective pathways are blocked in this model of acute CCl4 
intoxication. 
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Figure 4.3.5: Uric acid and potassium serum levels. (A) Uric acid levels increased significantly 48 
hours after CCl4 treatment. The rise was significantly higher when IL-6 Transsignaling was blocked 
(sgp130Fc, grey bars). Enhancement of Transsignaling with a single, previous injection of Hyper-IL-6 
led to significant lower uric acid levels. Unpaired student`s t test: * P< 0.05; ** P< 0.005. (B) Potassium 
levels increased slightly in sgp130Fc pretreated mice 48 hours after CCl4 treatment.  
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4.4 Quantification of lipid peroxidation by measuring TBARS 
Thiobarbituric acid reactive substances (TBARS) are an index of lipid peroxidation 
and oxidative stress and were measured in liver tissue homogenate 0 to 6 hours after 
CCl4 treatment.  
4 hours after CCl4 induced liver damage, TBARS levels of sgp130Fc pretreated mice 
peaked at 7 µM, which was significantly higher than in CCl4 only treated mice, where 
TBARS values reached only 4 µM (P< 0.05). In mock treated mice TBARS held at 
basic levels of 0.5 µM.  
6 hours after CCl4 treatment TBARS declined but stayed significantly higher in livers 
of mice with blocked IL-6 Transsignaling (P< 0.05) (Fig. 4.4.1).  
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Figure 4.4.1: Evaluation of oxidative stress by TBARS quantifications. C57Bl/6N mice were 
treated with CCl4 after previous injection of sgp130Fc or mock treatment. TBARS were measured in 
total protein lysates at the indicated time points after the intoxication. Values increased significantly in 
sgp130Fc pretreated mice 4 and 6 hours after CCl4 treatment (*P< 0.05).  
 
 
4.5 Expression levels of P450 2E1 (Cyp2E1) 
The mechanism of oxidative liver damage after CCl4 treatment depends on 
biotransformation of CCl4 into the free radicals CCl3• and CCl3O2•. This process is 
catalyzed by Cytochrome P450 2E1 which is located in the endoplasmatic reticulum 
of hepatocytes.  
To proof that in all different CCl4 treated groups has developed the same amount of 
bioactivated radicals, protein expression levels of Cyp2E1 were measured. For this 
purpose microsomes were isolated from livers of CCl4 treated animals. Proteins were 
isolated from microsome preparations and immuno blotting against Cyp2E1 was 
carried out.  
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24 hours after the CCl4 treatment was detected an induction of Cyp2E1, whereas in 
mock treated mice almost no enzyme expression was detectable. Equal loading of 
protein was controlled with ponceau stainings (Fig. 4.5.1).  
This experiment indicates that the different extent of CCl4 induced liver damage is not 
due to different Cyp2E1 protein expression levels.  
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Figure 4.5.1: Expression of Cytochrome P450 2E1 (Cyp2E1). C57Bl/6N mice were treated with 
CCl4 after previous injection of sgp130Fc or mock treatment. Microsomes were prepared from livers 
24 hours after liver damage and immuno blotting analysis for Cyp2E1 was carried out. Equal protein 
amounts were controlled with Ponceau staining.  
 
 
4.6 Inflammatory response: Quantification of IL-6 level 
IL-6 is considered to be a main mediator of inflammatory responses. IL-6 levels were 
measured within the sera or liver protein lysates of CCl4 treated mice at different time 
points after liver injury.  
6 hours post CCl4 injection, a 2-fold increase of IL-6 in the sera of sgp130Fc 
pretreated mice was detected (2,000 pg/ml) compared to CCl4 only treated mice (ca 
1,000 pg/ml) and to Hyper-IL-6 pretreated mice (ca 800 pg/ml) (P< 0.0001).  
24 hours after CCl4 induced liver damage, IL-6 serum levels were significantly 
elevated in sgp130Fc pretreated mice (ca 3,000 pg/ml) compared to CCl4 only 
treated (2,000 pg/ml) and Hyper-IL-6 pretreated animals (2,000 pg/ml) (P< 0.0001) 
(Fig. 4.6.1A). 
Within protein lysates of liver tissue, elevated IL-6 levels in sgp130Fc pretreated mice 
were detected 6 hours after CCl4 treatment compared to CCl4 only (P< 0.05) and 
Hyper-IL-6 pretreated mice (P< 0.0001).  
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24 and 48 hours after CCl4-induced liver damage IL-6 levels increased in liver 
homogenates compared to mock control. There was no significant difference 
between the groups detectable (Fig. 4.6.1B). 
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Figure 4.6.1: IL-6 expression after CCl4 induced damage. (A) IL-6 was measured in serum at the 
indicated time points. IL-6 levels increased after CCl4 treatment. The rise is significantly higher in 
sgp130Fc pretreated mice 6 hours and 24 hours after treatment. (B) IL-6 was measured in liver lysates 
in pg/ml per µg lysate at the indicated time points. IL-6 lysate levels increased after CCl4 treatment. 
The increase is significantly higher in sgp130Fc pretreated mice 6 hours after CCl4 treatment. 
Unpaired student`s t test: * P< 0.05; ***P< 0.0001. 
 
 
4.7 STAT 3 phosphorylation 
IL-6 stimulation via the membrane-bound or via the soluble IL-6 Receptor leads to 
activation and dimerization of two gp130 molecules and therewith to activation of the 
STAT3 signaling cascade. 
After 0, 2, 4 and 6 hours liver extracts of CCl4 only and sgp130Fc pretreated mice 
were prepared and immuno blotting analysis for P-STAT3, STAT3, and β-actin was 
carried out. 0 hours after the intoxication no STAT3 phosphorylation was visible. 2 
hours after CCl4 induced liver damage a beginning STAT3 phosphorylation could be 
detected, which is peaking in intensity 4 hours after the intoxication and declining 6 
hours after the liver damage. The STAT3 phosphorylation in sgp130Fc pretreated 
mice is diminished compared to CCl4 only treated mice (Fig. 4.7.1). 
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Figure 4.7.1: Expression of P-STAT3. C57Bl/6N mice were treated with CCl4 after previous injection 
of sgp130Fc or mock treatment. Lysates were prepared from livers 0, 2, 4 and 6 hours after CCl4 and 
immuno blotting analysis for P-STAT3, STAT3 and ß-actin was carried out.  
 
 
4.8 Acute phase response after CCl4 treatment 
IL-6 promotes inflammatory events through the expansion and activation of T-cells, 
differentiation of B-cells and the induction of acute-phase substances by 
hepatocytes. Furthermore IL-6 is produced in large amounts by endothelial cells in 
response to proinflammatory signals including TNF-α and hypoxia. 
Due to the proinflammatory properties of IL-6 and the detection of large amounts of 
IL-6 in the sera and liver lysates after CCl4 induced damage, the acute phase 
response in this liver damage model was analyzed. 
Serum amyloid A (SAA) proteins are a family of apolipoproteins associated with high-
density lipoprotein (HDL) in plasma. Different isoforms of SAA (mainly SAA1, SAA2 
and SAA3) are expressed in response to inflammatory stimuli. These proteins are 
produced predominantly by hepatocytes and are induced by the proinflammatory 
cytokines IL-1, IL-6, and TNF-α e.g. following exposure to lipopolysaccharide (LPS). 
An additional acute phase response protein is haptoglobin, which is predominantly 
expressed by hepatocytes and is, like the SAAs, IL-6 dependent. 
 
After RNA extraction and reverse transcription, TaqMan-based “gene expression 
assays” for SAA1, SAA3, Haptoglobin and β2-microglobulin were performed on an 
ABI-Prism/7000 Sequence Detection System. Primers for SAA1 are localized around 
exon 3-4 boundary, primers for SAA3 are localized around exon 2-3 boundary, 
primers for haptoglobin are localized around exon 4-5 boundary, and primers for ß2-
microglobulin are localized around exon 1-2 boundary. All data were analyzed in 
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duplicates and mRNA expression levels were normalized to ß2-microglobulin as 
expression control. The expression level of only CCl4 treated mice was set to 1. All 
other values were given as fold control of expression.  
Surprisingly, 6 hours after the CCl4 induced liver damage, mRNA levels of SAA1, 
SAA3 and haptoglobin were increased in sgp130Fc pretreated mice in comparison to 
CCl4 only treated mice. SAA1 and SAA3 levels were 6 fold increased when 
compared to CCl4 only treated mice, haptoglobin was 2 fold increased in sgp130 
pretreated mice (Fig. 4.8.1). 
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Figure 4.8.1: RealTime PCR analysis of acute phase response. mRNA of the acute phase 
response genes SAA1 (A), SAA3 (B) and Haptoglobin (C) were measured in liver tissue 6 hours after 
treatment with CCl4 after previous injection with PBS (black bars), sgp130Fc (grey bars) and PBS 
control animals (striped bars). mRNA expression levels were normalized to ß2-microglobulin as 
expression control. Expression level of only CCl4 treated C57Bl/6 mice was set to 1. All other values 
are given as fold control of expression.  
 
In an additional experimental data set 10-12 weeks old male C57/Bl6N mice were 
injected with 3 ml CCl4 per kg body weight, pretreated with 250 µg sgp130Fc i.p. (18 
hours before intoxication), injected with 250 µg sgp130Fc alone i.p. (18 hours before 
intoxication) or injected with 1 µg IL-6 i.p. (2 hours before intoxication). 6 hours after 
CCl4 treatment were the mice sacrificed. 
After RNA extraction and reverse transcription, TaqMan-based “gene expression 
assays” for SAA1 and β2-microglobulin were performed on an ABI-Prism/7000 
Sequence Detection System. All data were analyzed in duplicates and mRNA 
expression levels were normalized to ß2-microglobulin as expression control. The 
expression level of only sgp130Fc treated C57Bl/6 mice was set to 1.  
6 hours after CCl4 injection, SAA1 mRNA levels of sgp130Fc + CCl4 treated mice 
were increased 10 fold, mRNA levels of CCl4 only treated mice 1.5 fold and mRNA 
levels of IL-6 treated mice were increased 3 fold compared to sgp130Fc only treated 
animals (Fig. 4.8.2). 
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Figure 4.8.2: RealTime PCR analysis of SAA1. SAA1 was measured in liver tissue 6 hours after 
CCl4, with pretreatment with sgp130Fc, with sgp130Fc alone, or with 1 µg IL-6 (all treatments i.p.). 
mRNA expression levels were normalized to ß2-microglobulin as expression control. The expression 
level of only sgp130Fc treated C57Bl/6 mice was set to 1. All other values are given as fold control of 
expression.  
 
To determine the onset of acute phase gene expression, different time points were 
analyzed. 
After RNA extraction and reverse transcription, TaqMan-based “gene expression 
assays” for SAA1, SAA3 and β2-microglobulin were performed on an ABI-Prism/7000 
Sequence Detection System. All data were analyzed in duplicates and mRNA 
expression levels were normalized to ß2-microglobulin as expression control. The 
expression level of solvent control treated C57Bl/6 mice was set to 1.  
4 hours after CCl4 induced liver damage SAA1 mRNA levels were elvated in CCl4 
only and sgp130Fc pretreated mice to around 10 fold compared to mock control 
animals. 6 hours after the intoxication SAA1 mRNA levels peaked in sgp130Fc 
pretreated mice to a 40 fold increase compared to mock treated mice, whereas SAA1 
mRNA levels of CCl4 only treated mice remained at levels about 10 fold increase 
(Fig. 4.8.3A). 
SAA3 mRNA levels were increased 4 hours after CCl4 induced liver damage. CCl4 
only treated mice developed levels of around 8 fold increase, while sgp130Fc 
pretreated mice displayed levels of about 20 fold increase compared to mock treated 
mice. 6 hours after the intoxication SAA3 mRNA levels were declining (Fig. 4.8.3B). 
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Figure 4.8.3: RealTime PCR analysis of acute phase response genes. The acute phase response 
genes SAA1 (A) and SAA3 (B) were measured at the indicated time points. mRNA expression levels 
were normalized to ß2-microglobulin as expression control. The expression level of mock treated 
C57Bl/6 mice was set to 1. All other values are given as fold control of expression.  
 
 
4.9 Impact of IL-6 Transsignaling on glycogen content within the 
liver 
Glycogen was stained within liver sections using Periodic Acidic Schiff (PAS) 
staining. After 24h, livers were almost empty of glycogen, whereas livers of mock 
treated mice contained usual amounts of glycogen. 48h after CCl4 treatment, 
glycogen was reestablished in CCl4 only treated and Hyper-IL-6 pretreated animals, 
whereas livers of sgp130Fc pretreated mice still lacked glycogen (Fig. 4.9.1). These 
findings indicate that IL-6 Transsignaling has an influence on the glycogen 
metabolism or the kinetic of glycogen synthesis after CCl4 induced liver damage.  
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Figure 4.9.1: Glycogen staining of liver sections after CCl4 injection. PAS stainings of liver 
sections showed a regular glycogen restoration 48 hours after CCl4 injection in CCl4 treated and 
Hyper-IL-6 pretreated mice, when compared to sgp130Fc pretreated animals, whereas livers of 
sgp130Fc pretreated mice still lacked glycogen. 
 
After 6 and 48 hours liver extracts of CCl4 only, Hyper-IL-6 pretreated, and sgp130Fc 
pretreated mice were prepared and immuno blotting analysis for P-GSK-3ß and β-
actin was carried out. 
6 hours after CCl4 induced liver damage, an increase of P-GSK-3ß was detectable, 
which declined 48 hours after CCl4 injection. Hyper-IL-6 treated animals showed the 
same tendencies, whereas sgp130Fc pretreated mice displayed a sustained GSK-3ß 
phosphorylation even 48 hours after the damage (Fig. 4.9.3). 
There is evidence that 48 hours after the CCl4 intoxication, the glycogen synthase is 
still active in sgp130Fc pretreated mice, whereas in CCl4 only or Hyper-IL-6 
pretreated mice the glycogen synthase is inactive (Fig. 4.9.2).  
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Figure 4.9.2: Schematic illustration of glycogensynthase.  The glycogensynthase is activated 
(green) when GSK-3 is inactivated by phosphorylation. When GSK-3 is dephosphorylated, the 
Glycogensynthase is inhibited (red). GSK-3: Glycogen-synthase-kinase-3, P-GSK-3: Phosphorylated 
Glycogen-synthase-kinase-3 
 
After RNA extraction and reverse transcription, TaqMan-based “gene expression 
assays” for GSK-3ß and β2-microglobulin were performed on an ABI-Prism/7000 
Sequence Detection System. Primers for GSK-3ß are localized around exon 8-9 
boundary and primers for ß2-microglobulin are localized around exon 1-2 boundary. 
All data were analyzed in duplicates and mRNA expression levels were normalized to 
ß2-microglobulin as expression control. 
6, 24 and 48 hours after CCl4 induced liver damage, mRNA expression levels of CCl4 
only and sgp130Fc pretreated mice achieved comparable amounts of GSK-3ß (Fig. 
4.9.4). 
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Figure 4.9.3: Phosphorylation state of GSK-3ß. C57Bl/6N mice were treated with CCl4 after 
previous injection of sgp130Fc or mock treatment. Lysates were prepared from livers 6 and 48 hours 
after liver damage and immuno blotting analysis for P-GSK-3ß and ß-actin was carried out. 6 hours 
after CCl4 intoxication, a pronounced GSK-3ß-phosphorylation was visible. 48 hours after the liver 
damage, GSK-3ß phosphorylation is still detectable in sgp130Fc pretreated mice, but not in CCl4 only 
and Hyper-IL-6 pretreated animals. 
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Figure 4.9.4: RealTime PCR analysis of GSK-3ß. Glycogen synthase kinase 3 (GSK-3ß) was 
measured in liver tissue at the indicated time points. mRNA expression levels were normalized to ß2-
microglobulin as expression control. The expression level of solvent treated C57Bl/6 mice was set to 
1. All other values are given as fold control of expression in solvent control animals. GSK-3ß gene 
expression of CCl4 only and sgp130Fc pretreated mice reached comparable amounts. 
 
4.10 Quantification of liver regeneration via BrdU-incorporation 
Liver regeneration was quantified via BrdU stainings. Two hours prior to sacrificing, 
mice were injected with BrdU. Positive cells were visualized immunhistochemically 
and representative pictures and quantification were carried out.  
48 hours after CCl4 induced liver damage, a diminished number of BrdU positive 
hepatocytes were detected in liver sections of sgp130Fc pretreated mice. In 
comparison, in liver sections of CCl4 only and Hyper-IL-6 pretreated animals were 
detected higher numbers of BrdU positive hepatocytes (Fig. 4.10.1A). 
Quantification of given pictures offered significantly reduced percentage of BrdU 
positive cells in sgp130Fc pretreated mice of around 15 %, in comparison to about 20 
% positive cells in CCl4 only (P< 0.0001) and Hyper-IL-6 pretreated mice (P< 0.005) 
(Fig. 4.10.1B). 
We concluded that regeneration depends in parts on signaling via IL-6/sIL-6R, since 
a blockade of this pathway led to a reduction of proliferating cells.  
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Figure 4.10.1: Bromodeoxyuridine (BrdU) staining and quantification. (A) BrdU staining of liver 
sections 48 hours after treatment with CCl4 in 20 fold magnification. Two hours prior to sacrificing, 
mice were injected with 10 µg/µl BrdU i.p. Positive cells were visualized immunhistochemically. (B) 
Quantification of liver sections of sgp130Fc pretreated mice showed significantly less BrdU positive 
cells compared to CCl4 only and Hyper-IL-6 pretreated mice. Unpaired student`s t test: ** P< 0.005; 
***P< 0.0001. 
 
 
4.11 Impact of neutrophils on the severity of CCl4-induced liver 
damage 
It is known that in case of tissue damage or inflammation, neutrophils are infiltrating 
into the tissue. To determine the role of neutrophils after CCl4 treatment, we depleted 
neutrophils in CCl4 and sgp130Fc pretreated mice and investigated the impact of this 
neutrophil depletion on the severity of liver damage.  
Therefore C57/Bl6N mice were injected with 100 µg of a purified rat anti-mouse 
Ly6G/Ly6C monoclonal antibody 18 hours before CCl4 injection and sacrificed 24 
hours later. Depletion was controlled by staining of neutrophils on paraffin tissue 
sections.  
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Measuring ALT levels revealed that depletion of neutrophils reduced the liver 
damage in both groups:  
C57Bl/6 mice developed 24 hours after CCl4 treatment ALT serum levels of around 
7,500 U/L. When these animals were pretreated with the neutrophil depleting 
antibody, ALT levels were significantly reduced to about 2,500 U/L (P< 0.0001). 
C57/Bl6 mice, in which IL-6 Transsignaling is blocked, developed 24 hours after CCl4 
treatment ALT serum levels of around 15,000 U/L, which is significantly higher than in 
mice with intact IL-6 Transsignaling (P< 0.0001). When these animals were 
pretreated with the neutrophil depleting antibody, ALT levels were significantly 
reduced to about 10,000 U/L (P< 0.0001) (Fig. 4.11.1A). Neutropenia led in both 
groups to an ALT reduction of around 5,000 U/L. 
The presence of sgp130Fc was demonstrated by sgp130 Elisa (Fig. 4.11.1B). 
These findings demonstrate that neutrophil depletion reduces the amount of liver 
damage, even when IL-6 Transsignaling is blocked. Neutrophils are therefore in this 
model no explanation for the observed higher damage in the sgp130Fc treatment 
group, which is also shown in blood flow cytometry analysis (Fig. 4.11.2). 
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Figure 4.11.1: Measurement of ALT serum levels in neutrophil depleted mice. (A) C57Bl/6N mice 
were treated with CCl4 after previous injection of sgp130Fc or mock treatment. Both groups were 
either pretreated with the neutrophil depleting antibody anti-mouse Ly6G/Ly6C 18 hours before CCl4 
or received no depleting antibody. Mice were sacrificed 24 hours after the CCl4 treatment and ALT 
serum levels were measured. (B) Serum sgp130Fc levels were measured via ELISA 24 hours after 
CCl4 intoxication. Unpaired student`s t test: ** P< 0.005; ***P< 0.0001. 
 
C57/Bl6N mice were treated with CCl4 after previous injection of sgp130Fc or mock 
treatment. After 0, 2 and 4 hours blood samples were taken and blood flow cytometry 
analysis was performed using a FITC Ly6G and a PE CD11b antibody. Quantitative 
analysis revealed increasing numbers of neutrophils 4 hours after CCl4 in both 
groups (Fig. 4.11.2A). 
In a second experiment sgp130 transgenic and C57/Bl6 mice were treated with 3 
ml/kg body weight CCl4. After 6, 24 and 48 hours blood samples were obtained and 
flow cytometry analysis was performed. Quantitative analysis showed a peak of 
neutrophils 24 hours after the damage in both groups with no differences between 
the groups (Fig. 4.11.2B). 
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Figure 4.11.2: Quantitative blood flow cytometry analysis of neutrophils. (A) C57Bl/6N mice were 
treated with CCl4 after previous injection of sgp130Fc or mock treatment. Quantitative blood flow 
cytometry analysis of neutrophils in percent at the indicated timepoints after CCl4 induced liver 
damage was carried out. (B) C57Bl/6N and sgp130 transgenic mice were treated with CCl4. 
Quantitative blood flow cytometry analysis of neutrophils in percent at the indicated timepoints after 
CCl4 induced liver damage was performed.  
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5 Discussion 
 
5.1 CCl4 induced liver damage 
In the present work I could show that liver damage and regeneration in response to 
acute CCl4 liver damage was strongly influenced by IL-6 Transsignaling. sgp130 is a 
natural, specific inhibitor of IL-6 Transsignaling (63) and we have developed a 
sgp130Fc fusion protein to block IL-6 Transsignaling without influencing classical IL-6 
signaling (100).  
Acute liver damage was induced with a single i.p. injection of 3 ml/kg body weight 
CCl4 in various mouse groups. Either IL-6 Transsignaling was blocked with a single 
i.p. injection of sgp130Fc, or IL-6 Transsignaling was accelerated with a single i.p. 
injection of Hyper-IL-6. For the control group, mice which received no pretreatment 
were used. Thus, the control group mice developed a normal induction of IL-6 
Transsignaling response to CCl4 induced liver damage.  
The extent of liver damage between the various groups was analyzed at different 
timepoints, starting with early timepoints at 2 to 6 hours and proceeding with 24 and 
48 hours. A number of different parametes indicative of liver damage were quantified. 
It can be concluded that IL-6 Transsignaling has an positive effect on the extent of 
induced liver damage, the amount of oxidative stress, IL-6 levels, the induction of 
acute phase response and finally on liver glycogen content and regeneration. 
 
 
5.2 Impact of blocked IL-6 Transsignaling on lipid peroxidation 
CCl4 is metabolized by the P450 mixed function oxygenase system of the 
endoplasmatic reticulum to the free radical, CCl3• (83, 101). The major cytochrome 
isoenzyme to execute biotransformation of CCl4 is Cyp2E1, but Cyp2B1 and Cyp2B2 
are also capable of attacking CCl4 (102, 103). The resulting CCl3• radical is able to 
bind covalently to the active site or to the heme group of Cyp2E1, thereby causing 
suicide inactivation of Cyp2E1 (104-107). The CCl3• radical reacts with various 
biologically important substances such as aminoacids, nucleotides, fatty acids, 
proteins, nucleic acids, and lipids. In the presence of oxygen, the CCl3• radical is 
converted to the trichloromethyl peroxy radical, CCl3O2•. This radical is more reactive 
than the CCl3• radical, and is abstracting a hydrogen from polyunsaturated fatty acids, 
thereby initiating the process of lipid peroxidation (108-112). The abstraction of a 
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hydrogen from fatty acids initiates a complex series of reactions that terminate in the 
complete disintegration of the polyunsaturated fatty acids by compromising 
membrane functions and by covalent binding of reactive intermediates.  
Oxidative stress is commonly quantified via the amount of lipid peroxidation in liver 
tissue, using thiobarbituric acid reactive substances (TBARS) as a marker. Katz et al 
showed that IL-6 deficient mice exhibit higher lipid peroxidation after CCl4 treatment 
than C57/Bl6 control mice (93), allocating IL-6 a crucial role in this process.  
Donato et al. reported that an increase of IL-6 in endothelial cells led to enhanced 
activity of NADPH oxidase and therewith to increased amounts of reactive oxygen 
species. Due to the endothelial dysfunction, this results finally in atherosclerosis 
(113). 
In the present work I could show significantly increased lipid peroxidation 4 and 6 
hours after CCl4 treatment when IL-6 Transsignaling was blocked with sgp130Fc, 
compared to control mice (Fig. 4.4.1). These differences in lipid peroxidation 
appeared to be independent of the metabolized amount of radicals, as protein 
expression levels of Cyp2E1 are comparable in sgp130Fc pretreated and control 
mice (Fig. 4.5.1). Nevertheless it is not possible at the moment to monitor the extent 
of detoxifying activities, which are occuring after CCl4-induced acute liver damage. 
Other parameters for oxidative stress or common cell damage are uric acid and 
potassium in blood serum. Apart from the fact that uric acid is the final oxidation 
product of purine metabolism and is excreted in urine, uric acid plays a protective role 
in defending organs and tissue from oxidative damage by attenuating oxidation of 
plasma lipids, lipoproteins, and unsaturated fatty acids. A critical role for uric acid in 
antioxident defense and lipid peroxidation has been identified in human blood plasma 
(96-99). 
Potassium plays a crucial role in maintenance of membrane potential. The 
intracellular concentration is up to 40 times higher than the extracellular 
concentration. Therefore serum potassium could be used as a marker for general cell 
damage. 
A specific upregulation in uric acid and potassium, sera levels was found in mice with 
blocked IL-6 Transsignaling 24 and 48 hours after the CCl4-induced liver damage 
(Fig. 4.3.5). This indicates that there is increased oxidative stress present in the 
absence of intact Transsignaling. These results imply that IL-6 Transsignaling 
protects cells from oxidative stress. 
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Furthermore, varios parameters of liver damage were quantified. Serum ALT and 
AST levels were found to be significantly higher when IL-6 Transsignaling was 
blocked 24 and 48 hours after CCl4 induced liver damage (Fig. 4.3.1). This enhanced 
liver damage was also visible morphologically in Hematoxylin/Eosin stainings 
showing massive necrotic areas. DAPI stainings show more intact nuclei in livers of 
mice with intact IL-6 Transsignaling (Fig. 4.3.3 and Fig. 4.3.4).  
These data indicate that the extent of liver damage is significantly controlled by IL-6 
Transsignaling, which could be the consequence of reduced reactive oxygen species 
and free radicals. 
 
 
5.3 Impact of IL-6 Transsignaling on IL-6 induction 
TNFα is a proinflammatory cytokine with pleiotrophic effects and multiple roles in 
host defense. TNFα has a pivotal role in liver pathophysiology, because it can either 
induce hepatocyte cell death or hepatocyte proliferation and liver regeneration. TNFα 
is produced mainly by macrophages but also by a broad variety of other cell types 
including lymphoid cells, mast cells, endothelial cells, fibroblasts and neuronal cells 
(114). TNFα is primarily produced as a type II transmembrane protein but may be 
released in soluble trimeric form via proteolytic cleavage by the metalloprotease TNF-
converting enzyme (TACE) (114). In response to LPS and other bacterial products, 
large amounts of TNFα are generated. TNFα exerts its biological functions via 
interactions with two different membrane receptors, TNF-R1 and TNF-R2. TNFα can 
induce apoptosis via the intracellular death domain of TNF-R1, but it can also initiate 
signaling pathways leading to the activation of the transcription factor nuclear factor-
κB (NF-κB), and therefore via MAPK cascades and JNK to a prevention of apoptosis 
and to proliferation. 
TNFα signaling is required for normal liver regeneration. Mice lacking the TNF-R1 
subunit display abnormal and delayed regeneration after partial hepatectomy (115). 
Lack of TNF signaling can be overcome by a single injection of recombinant IL-6, 
suggesting that TNF functions mostly to release IL-6.  
In the initiation phase of liver regeneration, TNFα and IL-6 are responsible for priming 
of quiescent hepatocytes. This results in an induction of hepatocytes to become 
sensitive to growth factors and competent for replication. During proliferation phase, 
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hepatocytes enter into the cell cycle’s G1-phase and are stimulated by complete 
mitogens including hepatocyte growth factor (HGF), transforming growth factor-α 
(TGFα) and epidermal growth factor (EGF). 
The fact that IL-6 is of importance in the response to liver damage has already been 
described (70). IL-6 levels increase after liver injury induced by partial hepatectomy 
or chemical induced liver damage, and liver regeneration is markedly reduced in IL-6 
deficient mice. After partial hepatectomy, IL-6 deficient mice exhibit reduced 
regeneration rates and an impaired STAT3 activation (70).  
The important role of IL-6 has also been examined in the CCl4 liver damage model. 
Many of the molecular events are not mediated by hepatocytes, but by two types of 
nonparenchymal liver cells, e.g. Kupffer cells and stellate cells. Kupffer cells, the 
resident macrophages of  liver, are activated by CCl4 and release thereon TNFα, 
nitric oxide, TGFβ, and IL-1, IL-6 and IL-10 (82). Stellate cells, while quiescent, are 
fat-storing cells, but after activation of CCl4 display a typical acute phase response 
(116), release TGFα, nitric oxide and begin to overproduce type-1 collagen, which 
could result in liver fibrosis. 
 Early after CCl4 treatment, IL-6 expression increases. The source of IL-6 are mainly 
mesenchymal cells of the peritoneum induced by inflammatory cytokines like IL-1α, 
IL-1β, and TNFα (117). The increased IL-6 response is blunted in TNFαRI knockout 
mice (118). The consequences of this early IL-6 production are not fully understood. 
In the present work I could show that a modulation of the IL-6 Transsignaling 
pathway with sgp130Fc has an increasing effect on the amount of IL-6 production at 
early time points after the injury.  
In several experiments I demonstrated that IL-6 serum levels increased 6 to 24 hours 
after CCl4 induced liver damage (Fig. 4.5.1). This increase was significantly higher in 
sgp130Fc pretreated animals. This data show that IL-6 Transsignaling is involved in 
the regulation of IL-6 production at early time points after CCl4 induced liver damage.  
Focusing on the degree of liver damage induced by CCl4, it already has been shown 
that IL-6 and IL-6 signal pathways are involved in this process. Studies by Katz et. al. 
report that mortality rates are dose dependent and higher in IL-6 deficient mice (93). 
The role of IL-6 in modulating toxin-induced liver injury is still unclear. Following acute 
carbon tetrachloride treatment, IL-6-/- mice develop increased hepatocellular injury 
and defective regeneration as well as reduced hepatocyte DNA synthetic and mitotic 
responses (92). In contrast, chronical carbon tetrachloride treated IL-6-/- mice showed 
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reduced liver damage scores, lower aminotransferase levels and diminished 
apoptosis (94). 
IL-6 promotes inflammatory events through the induction of acute-phase proteins. 
Because of the proinflammatory properties of IL-6 and the production of large 
amounts of IL-6 in the sera and liver lysates after CCl4 induced damage, the acute 
phase response in this liver damage mouse model was analyzed. 
Different isoforms of SAA (mainly SAA1, SAA2 and SAA3), as well as haptoglobin 
and fibrinogen are expressed in response to inflammatory stimuli. These proteins are 
produced predominantly by hepatocytes and are induced by the proinflammatory 
cytokines IL-1, IL-6 and TNF-α under acute inflammatory conditions. 
6 hours after CCl4 induced liver damage, mRNA levels of SAA1, SAA3 and 
haptoglobin increased in sgp130Fc pretreated mice in comparison to CCl4 only 
treated mice. SAA1 and SAA3 increased 6 fold when compared with CCl4 only 
treated mice, haptoglobin increased 2 fold in sgp130 pretreated mice (Fig. 4.8.1). 
Blockade of IL-6 Transsignaling by sgp130Fc seemed to have an enhancing effect 
on the amount of induced acute phase response to CCl4. The IL-6 level in the sera of 
these mice, as well as in liver lysate, were elevated when IL-6 Transsignaling was 
blocked. This enhanced IL-6 response could be the source of the elevated acute 
phase response, although the levels of phosphorylated STAT3 was diminished in 
liver lysates of sgp130Fc treated mice (Fig. 4.7.1). 
 
 
5.4 The role of neutrophils  
Investigating possible explanations for these observations I focused on the impact of 
infiltrating neutrophils within the liver. It has been described that neutrophils have 
damaging effects in CCl4 induced liver damage. In previous studies Ohta et al (119) 
claim that CCl4 induced liver damage can be reduced by neutrophil depletion. In 
further studies it has been shown that the infiltration of neutrophils is controlled by IL-
6 Transsignaling. In an air-pouch model of acute inflammation, Rabe et al 
demonstrated that fewer neutrophils infiltrate to the site of inflammation when the IL-6 
Transsignal pathway is blocked (64). Nechemia-ArbelyIn et al displayed in a HgCl2-
induced acute kidney injury (AKI) model a critical role for IL-6 in recruiting 
neutrophils. IL-6-/- mice were resistant to HgCl2-induced AKI compared to wild-type 
mice. The accumulation of peritubular neutrophils was lower in IL-6-/- mice than in 
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wild-type mice, and neutrophil depletion before HgCl2 administration in wild-type mice 
significantly reduced AKI. Stimulation of IL-6 Transsignaling with Hyper-IL-6 activated 
STAT3 in renal tubular epithelium and prevented AKI, allocating IL-6 simultaneously 
an inflammatory response function and, through a mechanism of Transsignaling, a 
protective function for the kidney from further injury (120). 
In the model of CCl4 induced liver damage I could show that when neutrophils were 
depleted before CCl4 treatment, liver damage was reduced, becoming evident in 
decreased ALT serum level (Fig. 4.11.1 A). However, in the sgp130Fc pretreated 
mice, ALT levels were still higher than in CCl4 only treated animals. The amount of 
reduction in ALT levels due to the depletion of neutrophils was almost the same in 
mice with intact and blocked IL-6 Transsignaling (ca. 5000 U/L, Fig. 4.11.1 A).  
Moreover, flow cytometric analysis of blood samples were performed using a FITC 
Ly6G and a PE CD11b antibody. Quantitative analysis revealed increasing numbers 
of neutrophils in the blood 4 hours after CCl4 induced liver damage, peaking 24 hours 
after setting the damage. When IL-6 Transsignaling was blocked by sgp130Fc no 
major differences were observed in comparison to mice with intact IL-6 
Transsignaling (Fig. 4.8.2 and 4.8.3).  
I therefore hypothesize that the effect of IL-6 Transsignaling on the extent of CCl4 
induced liver damage is not dependent on neutrophils. 
 
 
5.5 Consequences to glycogen content and liver regeneration  
Closely related to induced liver damage is the subsequent induction of liver 
regeneration. Liver has an enormous potential to regenerate after injury, and the 
regeneration is clearly dependent on IL-6 signaling pathways.  
It has already been established that CCl4 affects hepatocellular levels of Ca2+ by 
compromising the ability of hepatocytes to maintain Ca2+ levels (121). Hepatocellular 
Ca2+ is sequestered into the three main compartments: cytosol (low Ca2+), 
endoplasmatic reticulum and mitochondria (both higher Ca2+). The loss of Ca2+ levels 
in ER and mitochondria therefore lead to a breakdown of the ATPase ion pumping 
systems (122, 123). 
CCl4 exposure activates phosphorylases, among others the glycogenphosphorylase, 
and causes glycogen depletion in the liver (124-126). Constant ATP levels could 
therefore prevent mortality caused by high dose of CCl4. 
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I could show via PAS staining that the glycogen content within the liver varies 
between the different treated groups: at early time points, 24 hours after CCl4 
injection, all glycogen was consumed in the liver. Within two days glycogen storages 
filled up in C57Bl/6 mice. However, when IL-6 Transsignaling was blocked this 
process was significantly impaired or slowed down (Fig. 4.9.1). The reasons for this 
phenomenon are not yet understood. Glycogen synthase kinase 3 (GSK-3) is a 
kinase, that mediates the addition of phosphate molecules on certain serine and 
threonine amino acids of glycogen synthase, which results in an inhibition of 
glycogen synthase. 
6 hours after CCl4 induced liver damage a strong phosphorylation of GSK-3ß was 
detectable in all CCl4 treated groups, which means an induction of glycogen synthase 
via inhibition of GSK-3ß. However 48 hours after the intoxication, GSK-3ß 
phosphorylation was still visible in mice with blocked IL-6 Transsignaling via 
sgp130Fc, whereas in CCl4 only and Hyper-IL-6 pretreated mice, very minor GSK-3ß 
phosphorylation was detectable (Fig. 4.9.2). 
Usually gp130 signaling leads to recruitment of phospoinositid-3-kinase (PI3K), which 
activates via phosphoinositoltriphosphat (PIP3) the phosphokinase B (PKB). PKB 
then phosphorylates the constitutively active glycogen-synthase-kinase-3 (GSK-3) 
and therewith inactivates it. In consequence, glycogen-synthase takes place (Fig. 
5.1). 
A blockade of IL-6 Transsignaling via sgp130Fc should lead to a reduction in gp130 
signaling, and therefore to less glycogen synthase due to less P-GSK-3. In fact I 
observed lower glycogen content in PAS stained livers of sgp130Fc pretreated mice 
48 hours after the liver damage in comparison to CCl4 only treated mice (Fig. 4.9.1). 
On the other hand, immuno blot analysis revealed a higher GSK-3 phosphorylation in 
livers of sgp130Fc pretreated mice 48 hours after the liver damage, when compared 
to CCl4 only treated animals (Fig. 4.9.2).  
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Figure 5.1: Simplified illustration of gp130 signaling. PI3K is recruited and activating PKB. PKB 
phosphorylates and therewith inactivates GSK-3. As a consequence of this inactivation, 
glycogensynthase takes place (green). When GSK-3 is dephosphorylated, the Glycogensynthase is 
inhibited (red). PI3K = phospoinositid-3-kinase, PIP3 = phosphoinositoltriphosphat, PKB = 
phosphokinase B and GSK-3 = glycogen-synthase-kinase-3. 
 
Sgp130Fc pretreated mice seem to require the glycogen synthase for a longer period 
of time to restore their glycogen stocks after CCl4 induced liver damage. This can be 
the consequence of more extensive damage, becoming evident in a reduced number 
of working ATPase, or that the IL-6 Transsignaling pathway is essential for glycogen 
metabolism.  
Interestingly, Drucker et al. obtained in a D-Gal induced damage model different 
results. In sgp130 transgenic mice glycogen consumption was inhibited after injection 
of D-Gal, when compared to WT mice, indicating that the sIL-6R is needed for the 
stimulation of glycogen consumption (127). 
I could further show that in C57Bl/6 mice, proliferation, quantified by BrdU 
incorporation, increased 48 hours after CCl4 injection compared to sgp130Fc 
pretreated mice. In mice with blocked IL-6 Transsignaling was less energy available, 
in the form of less glycogen within the liver. This finding could be one explanation for 
an impaired liver regeneration in sgp130Fc pretreated animals. 
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5.6 Clinical perspectives of sgp130Fc 
It is already known that IL-6 is involved in a number of chronic inflammation diseases. 
In 1997 a group in Japan began with the development of the humanized IL-6R 
antibody Tocilizumab, which is meanwhile applied in clinical trials to treat a number of 
chronic inflammatory diseases like rheumatoid arthritis (RA), juvenile idiopathic 
arthritis (JIA), multicentric Castleman disease (MCD), and lupus nephritis. Since 2009 
is Tocilizumab approved in Europe and since 2010 in USA for the treatment against 
RA.  
Treatment with Tocilizumab alleviated chronic inflammatory symptoms, e.g. 
improvements in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
fibrinogen and serum amyloid A (SAA) levels (128-132). 
Recently it has been demonstated that patients treated with Tocilizumab develop 
significantly increased serum levels of total cholestorol (TC), high-density lipoprotein 
(HDL), low-density lipoprotein (LDL), apolipoprotein A-1 (Apo A-1) and apolipoprotein 
A-2 (Apo A-2), as well as gained body weight after 3 months of treatment. Similarly, 
the serum levels of triglyceride (TG) and apolipoprotein B (Apo B) tended to increase, 
but were not significant (129, 133). 
In this regard, it should be noted that the mean serum LDL levels rise beyond 140 
mg/dl in Tocilizumab-treated patients, which can be an independent risk factor for 
cardiovascular events. These findings could be important, even though the serum 
levels of both HDL and LDL increased at the same time, and accordingly the 
atherogenic indices do not increase. Further analysis are therefore indispensable to 
determine the risk of elevated LDL levels during long-term use of Tocilizumab. 
While Tocilizumab blocks classical IL-6 signaling and IL-6 Transsignaling, sgp130Fc 
just affects IL-6 Transsignaling without interfering with classical IL-6 signaling. This 
could be a critical advantage of sgp130Fc in the treatment of chronic inflammatory 
diseases. Humanized sgp130Fc is at the moment in preclinical trials. The occuring 
side effects, especially concerning cardiovascular and atherosclerotic aspects, still 
have to be analyzed in detail. 
 
 
5.7 Outlook 
Taken together, these data demonstrate the protective effect of IL-6 Transsignaling 
on liver damage and regeneration in an acute CCl4-induced liver damage model. A 
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specific blockade of IL-6 Transsignaling led to increased IL-6 levels, enhanced liver 
damage and increased acute phase response. Reasons for these findings are still 
not fully understood, but they emphasize the importance of the endogenous IL-6 
Transsignaling pathway in CCl4 induced liver damage. Based on these results it 
should be taken into consideration that blocking IL-6 signaling pathways could be 
used as a treatment option in different inflammatory pathological states. In this work I 
showed that consequences of a blockade of IL-6 Transsignaling has very diverse 
effects on liver damage and regeneration in context of an acute CCl4 induced liver 
damage. In further experiments these findings should be compared with blocking 
both IL-6 pathways (IL-6 classical and IL-6 Transsignaling) by treatment with a 
neutralizing IL-6 antibody. The direct comparison of either blocking IL-6 
Transsignaling by sgp130Fc, or blocking classical and IL-6 Transsignaling by an IL-6-
antibody would be of great interest and a promising aim for the future. 
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6 Summary 
 
The liver has the unique capability to regenerate its mass after damage and injury.  
Nevertheless liver failure is still a serious medical problem and enhancing the 
regenerative potential of the liver could be an effective and promising therapy. 
Interleukin-6 is known to play an important role in mediating pro-mitotic and pro-
survival activities within the regenerative process. 
It already has been shown that IL-6 Transsignaling plays a crucial role in liver 
regeneration using the example of the effect of Hyper-IL-6 in accelerating liver 
regeneration following partial hepatectomy. 
Carbontetrachloride (CCl4) can be used to mimic drug induced hepatoxicity. Through 
the metabolization by cytochrome P450 dependent monooxygenase, the reactive 
CCl3•  and CCL3O2• radicals are formed which can covalently bind to proteins, lipids 
and nucleic acids and this could lead to lipidperoxidation and liver damage. 
The aim of the present study was to investigate the impact of IL-6 Transsignaling on 
liver damage and regeneration in this CCl4 induced liver damage mouse model. 
Therefore mice were treated with substances either blocking IL-6 Transsignaling 
(soluble gp130Fc) or accelerating IL-6 Transsignaling (Hyper-IL-6). Afterwards the 
mice were treated intraperitoneally with a single dose of CCl4, leading to acute liver 
damage. 
Mice in which IL-6 Transsignaling was blocked displayed higher liver damage, 
becoming evident in enhanced lipid peroxidation 4 to 6 hours after CCl4 treatment. 
Subsequently ALT and AST serum levels were strongly increased from 24 to 48 
hours after CCl4 treatment, with significantly higher levels in sgp130Fc pretreated 
mice. Moreover, uric acid and potassium serum level were elevated in mice with 
blocked IL-6 Transsignaling 48 hours after CCl4 injection. 
IL-6 serum level were elevated at early time points in mice pretreated with sgp130Fc 
compared to CCl4 only treated mice. As a consequence, acute phase genes like 
SAA1, SAA3 and haptoglobin were upregulated 6 hours after CCl4, although STAT-3 
phosphorylation was diminished. When IL-6 Transsignaling was blocked by 
sgp130Fc, mRNA levels of SAA1 and SAA3 increased 6 fold, mRNA levels of 
haptoglobin increased 2 fold compared to CCl4 only treated animals.  
In addition, glycogen storage was altered after blockage of IL-6 Transsignaling. 24 
hours after the damage all glycogen within the liver was consumed. While glycogen 
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storages were filled up in livers of mice with normal or accelerated IL-6 
Transsignaling, this process was significantly impaired when IL-6 Transsignaling was 
blocked. Animals pretreated with sgp130Fc showed lower BrdU incorporation, 
indicating a lower proliferation index. 
Overall, these data indicate a critical role of IL-6 Transsignaling in a CCl4 induced 
liver damage mouse model. 
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7 Zusammenfassung 
 
Die Leber besitzt die einzigartige Fähigkeit sich nach Schädigung oder Verletzung zu 
regenerieren. Dennoch stellt Leberversagen immer noch ein ernsthaftes 
medizinisches Problem dar, und eine Verbesserung des regenerativen Potenzials der 
Leber könnte eine effektive und vielversprechende Therapiemethode sein. 
Interleukin-6 ist für seine wichtige Rolle bei der Vermittlung von pro-mitotischen und 
überlebensfördernden Signalen innerhalb des regenerativen Prozesses bekannt. 
Es wurde schon mehrfach gezeigt, dass IL-6 Transsignaling eine entscheidende 
Rolle während der Leberregeneration spielt, welches sich am Beispiel von Hyper-IL-6 
verdeutlichen läßt. Hyper-IL-6 hat nach partieller Hepatektomie einen 
beschleunigenden Effekt auf die Leberregeneration. 
Kohlenstofftetrachlorid (CCl4) kann als Modell für medikamentös induzierten 
Leberschaden verwendet werden. Durch die Cytochrom P4502E1 abhängigen 
Monooxygenasen wird CCl4 zu den Radikalen CCl3•  and CCL3O2• umgesetzt. Die 
Radikale binden kovalent an Proteine, Lipide und Nukleinsäuren, was letztendlich zu 
Lipidperoxidation und Leberschädigung führt. 
Ziel der vorliegenden Arbeit war es, den Einfluss von IL-6 Transsignaling auf das 
Ausmaß von CCl4 induzierten Leberschaden und die Regenerationsfähigkeit zu 
bestimmen. 
Zu diesem Zweck wurden Mäuse mit unterschiedlichen Substanzen behandelt, die 
sich entweder blockierend (sgp130Fc) oder stimulierend (Hyper-IL-6) auf das IL-6 
Transsignaling auswirken. Anschließend wurden die Mäuse einmalig intraperitoneal 
mit einer akuten Leberschaden auslösenden CCl4 Dosis behandelt. 
Mäuse, in denen IL-6 Transsignaling blockiert war, entwickelten einen höheren 
Leberschaden, der in erhöhter Lipidperoxidation 4 und 6 Stunden nach CCl4 
Behandlung sichtbar wurde. Zusätzlich waren die ALT und AST Serumlevel nach 24 
und 48 Stunden stark erhöht, insbesondere in Mäusen, die zuvor mit sgp130Fc 
behandelt wurden. Außerdem waren, ebenfalls nach 48 Stunden, höhere Harnsäure-
und Kaliumwerte im Serum von Mäusen mit blockierten IL-6 Transsignaling 
detektierbar. 
Zu frühen Zeitpunkten waren die IL-6 Serumwerte erhöht, insbesondere in Mäusen, 
die mit sgp130Fc vorbehandelt worden sind. Als Konsequenz darauf wurden einige 
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Akut Phase Gene, wie SAA1, SAA3 und Haptoglobin, 6 Stunden nach CCl4 
Behandlung hochreguliert, obwohl die STAT3 Phosphorylierung vermindert war. 
In Tieren mit blockiertem IL-6 Transsignaling waren die SAA1 und SAA3 Werte 6 
Mal, und die Haptoglobin Werte doppelt so hoch, verglichen mit Tieren, die 
ausschließlich mit CCl4 behandelt wurden. 
Zusätzlich dazu war die Glycogenspeicherung verändert: 24 Stunden nach dem 
Schaden war der gesamte Glycogenspeicher der Leber bei allen Tieren verbraucht. 
Während sich in Mäusen mit intakten oder stimulierten IL-6 Transsignaling die 
Glycogenspeicher nach 48 Stunden bereits wieder gefüllt hatten, war der Prozess in 
Mäusen mit blockierten IL-6 Transsignaling deutlich vermindert. Diese Tiere zeigten 
ebenfalls eine geringere BrdU-Aufnahme, was auf eine geringere Proliferationsrate 
hindeutet. 
Insgesamt weisen diese Daten dem IL-6 Transsignaling eine wichtige Rolle im CCl4 
induzierten Leberschadenmodell zu. 
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9 Appendix 
9.1 Abbreviations 
 
A   Adenine 
ADAM  A Disintegrin And Metalloprotease 
AEC  3-Amino-9-Ethylcarbazol 
Ag  Antigen 
Akt  Proteinkinase B 
AKI  Acute kidney injury 
ALT  Alanine Aminotransferase 
APC   Allophycocyanin 
APP  Acute Phase Protein 
APS  Ammonium Persulfate 
AST  Aspartate Aminotransferase 
ATP   Adenosine 5'-Triphosphate 
 
BCA   Bicinchoninic Acid 
bp   Base Pairs 
BrdU  5-Bromo-2-Deoxyuridine 
BSA   Bovine Serum Albumin 
 
C   Cytosine 
CBM   Cytokine Binding Module 
CCl4  Carbontetrachloride 
cDNA  Complementary DNA 
CLC   Cardiotrophin-Like Cytokine 
CNTF  Ciliary Neutrotrophic Factor 
CNTFR Ciliary Neutrotrophic Factor Receptor 
ConA  Concanavalin A 
CRP   C-Reactive Protein 
CT-1   Cardiothrophin-1 
CYP  Cytochrome 
 
DAPI  4,6-Diamino-2-Phenylindole Dihydrochloride 
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dATP  Deoxy Adenosine Triphosphate 
D-Gal  D-Galactosamine 
dl  Deciliter 
DMSO  Dimethylsulfoxide 
DNA   Deoxyribonucleic Acid 
dNTP   2`-Desoxyribonucleotide-5´-Triphosphate 
DTT  Dithithreitol 
 
EAE  Experimental Autoimmune Encephalomyelitis  
ECL  Electrochemiluminescence 
EDTA  Ethylenediaminetetraacetic Acid 
EGF   Epidermal Growth Factor 
ELISA  Enzyme Linked Immunosorbent Assay 
ER   Endoplasmatic Reticulum 
Erk   Extracellular Signal Regulated Kinase 
EtOH  Ethanol 
 
FACS  Fluorescence Activated Cell Sorter 
Fc  Fragment Crystallizable  
Fig  Figure 
FITC  Fluorescein isothiocyanate 
 
G   Guanosine 
gp130  Glycoprotein 130 
Grb2   Growth Factor Receptor Bound Protein 2 
GSK-3 Glycogen Synthase Kinase 3 
 
h  Hour 
HB-EGF  Heparin Binding-Epidermal Growth Factor 
HDL  High Density Lipoprotein 
HE  Hematoxylin/ Eosin 
HGF  Hepatocyte Growth Factor 
hIL-6  human IL-6 
HRP  Horseradish Peroxidase 
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IB  Immunoblotting 
IFN α,γ Interferon α,γ 
Ig-domain  Immunoglobulin-Domain 
IL  Interleukin 
IL-6R  Interleukin-6 Receptor 
i.p.   Intraperitoneal Injection 
IVC   Individually Ventilated Cages 
 
JAK  Janus Kinase 
 
kb  Kilobase Pairs 
kDa  Kilodalton 
kg  Kilogram 
 
L  Liter 
LB   Lysogeny Broth 
LIF   Leukaemia Inhibitory Factor 
LIFR  Leukaemia Inhibitory Factor Receptor 
LPS  Lipopolysaccharide 
 
mAB  Monoclonal Antibody 
MAPK  Mitogen-Activated Protein Kinase 
MDA  Malondialdehyde 
min  Minute 
mg   Milligram 
ml  Milliliter 
mRNA Messenger RNA 
µg   Microgram 
µl  Microliter 
 
NADPH  Nicotinamide Adenine Dinucleotide Phosphate 
NFκB  nuclear factor of activated B-cells 
ng  Nanogram 
nm  Nanometer 
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NP   Neuropoietin 
 
OD   Optic Density 
OSM   Oncostatin M 
 
PARP  Poly ADP ribose polymerase 
PAS  Periodic Acidic Schiff 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
PE  Phytoerythrin 
Pfu  Pyrococcus Furiosus 
pg  Picogram 
PGSK-3 Phosphorylated Glycogen Synthase Kinase-3 
PI3K  Phosphoinositid-3-Kinase 
PIAS   Protein Inhibitors of Activated STAT 
PIP3  Phospho-Inositol-Phospate-3 
PKB  Protein Kinase B 
PKC   Protein Kinase C 
PMA   Phorbol 12-Myristate 13-Acetate 
POD  Peroxidase 
p-STAT3  Phospho-STAT3 
p value Probability 
PVDF  Polyvinylidene Fluoride 
 
RA   Rheumatoid Arthritis 
RNA   Ribonucleic Acid 
ROS   Reactive Oxygen Species 
rpm   Rounds Per Minute 
RT  Room Temperature 
RT-PCR  Reverse Transcriptase PCR 
 
SAA  Serum Amyloid A 
SCNTFR Soluble Ciliary Neutrotrophic Factor Receptor 
SD   Standard Deviation 
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SDS   Sodium Dodecyl Sulfate 
SDS-PAGE  SDS-Polyacrylamide Gel Electrophoresis 
sgp130  Soluble gp130 
SH2-domain  Src Homology-2 Domain 
SHP-2  Src homology protein 2 tyrosine phosphatase-2 
sIL-6R  soluble IL-6R 
SOCS  Suppressors Of Cytokine Signalling 
S-phase Synthesis Phase 
STAT   Signal Transducers and Activators of Transcription 
 
T   Thymine 
TACE  Tumor Necrosis Factor-Alpha Converting Enzyme (ADAM17) 
Taq  Thermus Aquaticus 
TBA  Thiobarbituric Acid 
TBARS  Thiobarbituric Acid Reactive Substances 
TBE   Tris Borate EDTA 
TBS   Tris Buffered Saline 
TEMED  N,N,N',N'-Tetramethylethylenediamine 
TGF   Transforming Growth Factor 
TMP  1,1,3,3-Tetramethoxypropane 
TNF   Tumor Necrosis Factor 
TNFR1  Tumor Necrosis Factor Receptor 1 
TNFR2  Tumor Necrosis Factor Receptor 1 
 
U   Units 
UV  Ultraviolette 
 
V  Volt 
v/v   Volume per Volume 
vIL-6   Viral interleukin-6 
 
w/v   Weight per Volume 
WT   Wildtype 
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9.2 Accession numbers 
 
ß2-microglobulin  Mm00437762_m1 
GSK-3ß   Mm00444911_m1 
Haptoglobin  Mm00516884_m1 
SAA1    Mm00656927_m1 
SAA3    Mm00441203_m1 
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Kenntnisse 
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